Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,600 | 2022-02-16 00:00:00 UTC | Amgen Snags Another Approval for This Promising Cancer Drug | ABBV | https://www.nasdaq.com/articles/amgen-snags-another-approval-for-this-promising-cancer-drug | null | null | Late last month, Japan's Ministry of Health, Labour and Welfare (MHLW) approved Amgen's (NASDAQ: AMGN) Lumakras to treat advanced non-small cell lung cancer (NSCLC) adult patients with the KRAS G12C mutation that worsened after prior therapy.
The MHLW gave Lumakras the nod just days after the European Commission approv... | And Amgen's biosimilar for AbbVie's (NYSE: ABBV) Humira, known as Amjevita, will launch in the U.S. next January, which could generate significant revenue for the company. See the 10 stocks *Stock Advisor returns as of January 20, 2022 Kody Kester owns AbbVie, Amgen, and Johnson & Johnson. Late last month, Japan's Mini... | And Amgen's biosimilar for AbbVie's (NYSE: ABBV) Humira, known as Amjevita, will launch in the U.S. next January, which could generate significant revenue for the company. See the 10 stocks *Stock Advisor returns as of January 20, 2022 Kody Kester owns AbbVie, Amgen, and Johnson & Johnson. Late last month, Japan's Mini... | And Amgen's biosimilar for AbbVie's (NYSE: ABBV) Humira, known as Amjevita, will launch in the U.S. next January, which could generate significant revenue for the company. See the 10 stocks *Stock Advisor returns as of January 20, 2022 Kody Kester owns AbbVie, Amgen, and Johnson & Johnson. Late last month, Japan's Mini... | And Amgen's biosimilar for AbbVie's (NYSE: ABBV) Humira, known as Amjevita, will launch in the U.S. next January, which could generate significant revenue for the company. See the 10 stocks *Stock Advisor returns as of January 20, 2022 Kody Kester owns AbbVie, Amgen, and Johnson & Johnson. Late last month, Japan's Mini... |
23,601 | 2022-02-15 00:00:00 UTC | Biohaven (BHVN) Migraine Drug Meets Study Goals in China | ABBV | https://www.nasdaq.com/articles/biohaven-bhvn-migraine-drug-meets-study-goals-in-china | null | null | Biohaven Pharmaceutical Holding Company Ltd. BHVN, along with partner Pfizer Inc. PFE, announced positive top-line data from a phase III study evaluating the safety and efficacy of the orally dissolving tablet (“ODT”) formulation of rimegepant for the acute treatment of migraine in China and South Korea.
The study met ... | In September 2021, the FDA approved AbbVie’s another oral CGRP receptor antagonist, Qulipta, as a preventive treatment of episodic migraine in adults. AbbVie’s ABBV oral CGRP, Ubrelvy, is approved for treating acute migraine. AbbVie believes that Ubrelvy and Qulipta represent a $1-billion-plus peak sales opportunity ea... | In September 2021, the FDA approved AbbVie’s another oral CGRP receptor antagonist, Qulipta, as a preventive treatment of episodic migraine in adults. AbbVie’s ABBV oral CGRP, Ubrelvy, is approved for treating acute migraine. AbbVie believes that Ubrelvy and Qulipta represent a $1-billion-plus peak sales opportunity ea... | AbbVie’s ABBV oral CGRP, Ubrelvy, is approved for treating acute migraine. In September 2021, the FDA approved AbbVie’s another oral CGRP receptor antagonist, Qulipta, as a preventive treatment of episodic migraine in adults. AbbVie believes that Ubrelvy and Qulipta represent a $1-billion-plus peak sales opportunity ea... | AbbVie’s ABBV oral CGRP, Ubrelvy, is approved for treating acute migraine. In September 2021, the FDA approved AbbVie’s another oral CGRP receptor antagonist, Qulipta, as a preventive treatment of episodic migraine in adults. AbbVie believes that Ubrelvy and Qulipta represent a $1-billion-plus peak sales opportunity ea... |
23,602 | 2022-02-15 00:00:00 UTC | Abbvie Inc Shares Climb 0.2% Past Previous 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-climb-0.2-past-previous-52-week-high-market-mover-0 | null | null | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $252B. The stock is currently up 6.7% year-to-date, up 43.3% over the past 12 months, and up 195.9% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%.
T... | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $252B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $252B. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.8%. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, ... | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $252B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jo... | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $252B. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-yea... |
23,603 | 2022-02-15 00:00:00 UTC | XLV, ABBV, TMO, MRK: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/xlv-abbv-tmo-mrk%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $341.6 million dollar inflow -- that's a 1.0% increase week over week in outstanding units (from ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is trading flat, and Merck & Co Inc (Symbol: MRK) is higher by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is trading flat, and Merck & Co Inc (Symbol: MRK) is higher by about 1.9%. For a complete list of holdings, visit the XLV Holdings page » The chart below shows the one ... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is trading flat, and Merck & Co Inc (Symbol: MRK) is higher by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... | Among the largest underlying components of XLV, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.2%, Thermo Fisher Scientific Inc (Symbol: TMO) is trading flat, and Merck & Co Inc (Symbol: MRK) is higher by about 1.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered... |
23,604 | 2022-02-14 00:00:00 UTC | 4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR | ABBV | https://www.nasdaq.com/articles/4-top-stock-trades-for-tuesday%3A-se-abbv-td-car | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Stocks were hit overnight, finding their footing near the open but coming under more selling pressure thanks to the escalating geopolitical tensions in Eastern Europe. Here are a few top stock trades to focus on going into the week.
Top Stock Trades for Tom... | Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) is a name I flagged this morning, as it has been one of the only strong stocks in the market lately. I don’t like trading these setups much — I prefer the TD and ABBV’s of the world — but CAR has investors’ attention with its giant, volatile move... | Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) is a name I flagged this morning, as it has been one of the only strong stocks in the market lately. The post 4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR appeared first on InvestorPlace. 2: AbbVie | 2: AbbVie Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) is a name I flagged this morning, as it has been one of the only strong stocks in the market lately. I don’t like trading these setups much — I prefer the TD and ABBV’s of the world — but CAR has investors’ attention with its giant, vol... | The post 4 Top Stock Trades for Tuesday: SE, ABBV, TD, CAR appeared first on InvestorPlace. 2: AbbVie Click to Enlarge Source: Chart courtesy of TrendSpider AbbVie (NYSE:ABBV) is a name I flagged this morning, as it has been one of the only strong stocks in the market lately. |
23,605 | 2022-02-14 00:00:00 UTC | 7 Dividend Aristocrats That Could Outpace This Volatile Market | ABBV | https://www.nasdaq.com/articles/7-dividend-aristocrats-that-could-outpace-this-volatile-market | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividend aristocrats are companies that have raised their dividend payments at least once a year for the past 25 years. Many of these names move on to become dividend kings that have increased payouts for 50 consecutive years. Investors who want sustainable... | 7 Industrial Stocks to Buy As Tech Stocks Tumble With that information, here are seven dividend aristocrats that could outperform today’s volatile market: AbbVie (NYSE:ABBV) Caterpillar (NYSE:CAT) Exxon Mobil (NYSE:XOM) Johnson & Johnson (NYSE:JNJ) Lowe’s (NYSE:LOW) NextEra Energy (NYSE:NEE) Nucor (NYSE:NUE) Dividend A... | 7 Industrial Stocks to Buy As Tech Stocks Tumble With that information, here are seven dividend aristocrats that could outperform today’s volatile market: AbbVie (NYSE:ABBV) Caterpillar (NYSE:CAT) Exxon Mobil (NYSE:XOM) Johnson & Johnson (NYSE:JNJ) Lowe’s (NYSE:LOW) NextEra Energy (NYSE:NEE) Nucor (NYSE:NUE) Dividend A... | 7 Industrial Stocks to Buy As Tech Stocks Tumble With that information, here are seven dividend aristocrats that could outperform today’s volatile market: AbbVie (NYSE:ABBV) Caterpillar (NYSE:CAT) Exxon Mobil (NYSE:XOM) Johnson & Johnson (NYSE:JNJ) Lowe’s (NYSE:LOW) NextEra Energy (NYSE:NEE) Nucor (NYSE:NUE) Dividend A... | 7 Industrial Stocks to Buy As Tech Stocks Tumble With that information, here are seven dividend aristocrats that could outperform today’s volatile market: AbbVie (NYSE:ABBV) Caterpillar (NYSE:CAT) Exxon Mobil (NYSE:XOM) Johnson & Johnson (NYSE:JNJ) Lowe’s (NYSE:LOW) NextEra Energy (NYSE:NEE) Nucor (NYSE:NUE) Dividend A... |
23,606 | 2022-02-14 00:00:00 UTC | Got $1,000? 5 Buffett Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/got-%241000-5-buffett-stocks-to-buy-and-hold-forever | null | null | Warren Buffett's investing savvy through his holding company Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) has made more millionaires than almost every other company in history. For instance, a $1,000 investment made in the stock when Buffett stepped in as CEO in 1965 would now be worth $18 million.
Though Buffett's in... | Recent approvals like Rinvoq's eczema indication in the U.S. should help AbbVie to quickly bounce back from Humira's U.S. patent expiration while earlier-stage drugs in development should secure the company's long-term future. AbbVie The first stock in Berkshire Hathaway's portfolio to buy is the pharma stock AbbVie (N... | AbbVie The first stock in Berkshire Hathaway's portfolio to buy is the pharma stock AbbVie (NYSE: ABBV), with Berkshire's stake in AbbVie currently valued at $2 billion. AbbVie's dividend yield of 4% is triple the S&P 500's 1.3%. And based on AbbVie's dividend payout ratio of 40.9% last year, the company has plenty of ... | AbbVie The first stock in Berkshire Hathaway's portfolio to buy is the pharma stock AbbVie (NYSE: ABBV), with Berkshire's stake in AbbVie currently valued at $2 billion. AbbVie's dividend yield of 4% is triple the S&P 500's 1.3%. And based on AbbVie's dividend payout ratio of 40.9% last year, the company has plenty of ... | AbbVie The first stock in Berkshire Hathaway's portfolio to buy is the pharma stock AbbVie (NYSE: ABBV), with Berkshire's stake in AbbVie currently valued at $2 billion. AbbVie's dividend yield of 4% is triple the S&P 500's 1.3%. And based on AbbVie's dividend payout ratio of 40.9% last year, the company has plenty of ... |
23,607 | 2022-02-14 00:00:00 UTC | Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals | ABBV | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-sanofi-abbvie-bristol-myers-amgen-and-vertex | null | null | For Immediate Release
Chicago, IL – February 14, 2022 – Today, Zacks Equity Research discusses Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX.
Industry: Big Pharma
Link: https://www.zacks.com/stock/news/1866486/will-the-rally-of-these-5-big-drugmakers-continue-in-2022
The broader... | For Immediate Release Chicago, IL – February 14, 2022 – Today, Zacks Equity Research discusses Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX. Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi, AbbVie, Bristol-Myers, Amgen a... | For Immediate Release Chicago, IL – February 14, 2022 – Today, Zacks Equity Research discusses Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX. Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi, AbbVie, Bristol-Myers, Amgen a... | Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals — that have outperformed their sector index as well as the wider Medical and S&P 500 indices. For Immediate Release Chicago, IL – February 14, 2022 – Today, ... | For Immediate Release Chicago, IL – February 14, 2022 – Today, Zacks Equity Research discusses Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX. Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi, AbbVie, Bristol-Myers, Amgen a... |
23,608 | 2022-02-14 00:00:00 UTC | Buffett's Berkshire bought Activision Blizzard before deal | ABBV | https://www.nasdaq.com/articles/buffetts-berkshire-bought-activision-blizzard-before-deal | null | null | Adds Daniel Loeb purchase
Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.Nloaded up on shares in video game maker Activision Blizzard Inc ATVI.O ahead of Microsoft Corp's MSFT.O $68.7 billion deal to buy the company, according to a regulatory filing.
Microsoft announced its acquisition of "Call of Duty... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. Adds Daniel Loeb purchase Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.Nloaded up... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. Adds Daniel Loeb purchase Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.Nloaded up... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. Adds Daniel Loeb purchase Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.Nloaded up... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. Adds Daniel Loeb purchase Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.Nloaded up... |
23,609 | 2022-02-14 00:00:00 UTC | Buffett's Berkshire buys Activision Blizzard, cuts healthcare positions | ABBV | https://www.nasdaq.com/articles/buffetts-berkshire-buys-activision-blizzard-cuts-healthcare-positions | null | null | By David Randall
Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it added nearly 14.7 million shares of video game maker Activision Blizzard Inc ATVI.O ahead of Microsoft Corp's MSFT.O $68.7 billion deal to buy the company.
The company also added to its position in energy giant Chevron ... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. By David Randall Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. By David Randall Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. By David Randall Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it... | The company also added to its position in energy giant Chevron Corp CVX.N while slicing its position in healthcare names including Bristol-Myers Squibb Co and Abbvie Inc ABBV.N during the quarter that ended in December. By David Randall Feb 14 (Reuters) - Warren Buffett's Berkshire Hathaway Inc BRKa.N said on Monday it... |
23,610 | 2022-02-12 00:00:00 UTC | Is the FDA's Partial Hold Bad News for Gilead Investors? | ABBV | https://www.nasdaq.com/articles/is-the-fdas-partial-hold-bad-news-for-gilead-investors | null | null | With Gilead Sciences' (NASDAQ: GILD) drug magrolimab now under a partial clinical hold with the U.S. Food and Drug Administration, how big of a setback could it be for the company? In this segment from "This Week in Healthcare," recorded on Jan. 31, Motley Fool contributors Brian Orelli and Keith Speights discuss what'... | AbbVie and Boehringer Ingelheim are a couple of other big drugmakers without anti-CD47 programs that they forward through licensing deals. Keith Speights owns AbbVie and Pfizer. In this segment from "This Week in Healthcare," recorded on Jan. 31, Motley Fool contributors Brian Orelli and Keith Speights discuss what's a... | AbbVie and Boehringer Ingelheim are a couple of other big drugmakers without anti-CD47 programs that they forward through licensing deals. Keith Speights owns AbbVie and Pfizer. With Gilead Sciences' (NASDAQ: GILD) drug magrolimab now under a partial clinical hold with the U.S. Food and Drug Administration, how big of ... | AbbVie and Boehringer Ingelheim are a couple of other big drugmakers without anti-CD47 programs that they forward through licensing deals. Keith Speights owns AbbVie and Pfizer. With Gilead Sciences' (NASDAQ: GILD) drug magrolimab now under a partial clinical hold with the U.S. Food and Drug Administration, how big of ... | AbbVie and Boehringer Ingelheim are a couple of other big drugmakers without anti-CD47 programs that they forward through licensing deals. Keith Speights owns AbbVie and Pfizer. In this segment from "This Week in Healthcare," recorded on Jan. 31, Motley Fool contributors Brian Orelli and Keith Speights discuss what's a... |
23,611 | 2022-02-11 00:00:00 UTC | 2 Dividend Stocks That Are Better Investments Than AT&T | ABBV | https://www.nasdaq.com/articles/2-dividend-stocks-that-are-better-investments-than-att | null | null | Investors in AT&T (NYSE: T) are likely down on the news that they will be collecting less in dividends from the telecom giant. An adjustment, however, wasn't a surprise given that the company was spinning off WarnerMedia and hinted last year that it would need to "resize" its dividend.
However, there are arguably bette... | This year, AbbVie expects to generate diluted per-share earnings between $9.26 and $9.46, which would put its payout ratio at 60%, leaving plenty of room for more rate hikes. With AbbVie, investors are getting a solid investment that in the past year generated a profit margin of 20% and is likely to remain a top growth... | Two high-yielding ones that investors might want to pivot to instead are Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV). AbbVie Drugmaker AbbVie pays a higher yield than IIP today at just over 4%. Over the past three years, their total returns (including dividends) have eclipsed those from AT&T: ... | However, AbbVie is a Dividend King and has an impressive track record for raising its dividend payments. With AbbVie, investors are getting a solid investment that in the past year generated a profit margin of 20% and is likely to remain a top growth stock to own for the foreseeable future. Two high-yielding ones that ... | Two high-yielding ones that investors might want to pivot to instead are Innovative Industrial Properties (NYSE: IIPR) and AbbVie (NYSE: ABBV). Over the past three years, their total returns (including dividends) have eclipsed those from AT&T: ABBV total return level. AbbVie Drugmaker AbbVie pays a higher yield than II... |
23,612 | 2022-02-11 00:00:00 UTC | Will the Rally of These 5 Big Drugmakers Continue in 2022? | ABBV | https://www.nasdaq.com/articles/will-the-rally-of-these-5-big-drugmakers-continue-in-2022 | null | null | The broader market index, S&P 500, has been declining since the beginning of 2022 as economy reel under the pressure of uncertainty related to macro factors, including interest rate hike, supply chain constraints and higher inflation.
The uncertainty around the macro factors has hurt the majority of medical sector indi... | Image Source: Zacks Investment Research Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX — that have outperformed their sector index as well as the wider Medical and S&P 500 indices. ... | Image Source: Zacks Investment Research Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX — that have outperformed their sector index as well as the wider Medical and S&P 500 indices. ... | Image Source: Zacks Investment Research Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX — that have outperformed their sector index as well as the wider Medical and S&P 500 indices. ... | Image Source: Zacks Investment Research Amid this turmoil, investors can place their bets on these five big pharma and biotech companies — Sanofi SNY, AbbVie ABBV, Bristol-Myers BMY, Amgen AMGN and Vertex Pharmaceuticals VRTX — that have outperformed their sector index as well as the wider Medical and S&P 500 indices. ... |
23,613 | 2022-02-11 00:00:00 UTC | 2 Green Flags For Gilead Sciences' Future | ABBV | https://www.nasdaq.com/articles/2-green-flags-for-gilead-sciences-future | null | null | Biotech giant Gilead Sciences (NASDAQ: GILD) has encountered its share of headwinds in the past two years. For instance, in late 2020 the company lost patent exclusivity in the U.S. for Truvada and Atripla -- both of which are HIV treatments -- leading to lower sales for both drugs.
Also, the drugmaker's much-anticipat... | According to some reports, Veklury became the medicine that hospitals in the U.S. spent the most money on last year, taking that spot away from AbbVie's Humira. While the past two years haven't been great for Gilead Sciences, they would have been substantially worse, financially speaking, had it not been for the impact... | According to some reports, Veklury became the medicine that hospitals in the U.S. spent the most money on last year, taking that spot away from AbbVie's Humira. Biotech giant Gilead Sciences (NASDAQ: GILD) has encountered its share of headwinds in the past two years. A leading COVID-19 therapy Gilead's Veklury was one ... | According to some reports, Veklury became the medicine that hospitals in the U.S. spent the most money on last year, taking that spot away from AbbVie's Humira. While the past two years haven't been great for Gilead Sciences, they would have been substantially worse, financially speaking, had it not been for the impact... | According to some reports, Veklury became the medicine that hospitals in the U.S. spent the most money on last year, taking that spot away from AbbVie's Humira. Biotech giant Gilead Sciences (NASDAQ: GILD) has encountered its share of headwinds in the past two years. Is Gilead Sciences a buy? |
23,614 | 2022-02-10 00:00:00 UTC | Notable Thursday Option Activity: DRI, GM, ABBV | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity%3A-dri-gm-abbv | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Darden Restaurants, Inc. (Symbol: DRI), where a total of 5,161 contracts have traded so far, representing approximately 516,100 underlying shares. That amounts to about 45.2% of DRI's average daily trading volume ove... | Particularly high volume was seen for the $145 strike call option expiring March 18, 2022, with 8,564 contracts trading so far today, representing approximately 856,400 underlying shares of ABBV. Below is a chart showing GM's trailing twelve month trading history, with the $57.50 strike highlighted in orange: And AbbVi... | Below is a chart showing GM's trailing twelve month trading history, with the $57.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 38,012 contracts, representing approximately 3.8 million underlying shares or approximately 43.1% of ABBV's average daily trading volume over the... | Below is a chart showing GM's trailing twelve month trading history, with the $57.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 38,012 contracts, representing approximately 3.8 million underlying shares or approximately 43.1% of ABBV's average daily trading volume over the... | Below is a chart showing GM's trailing twelve month trading history, with the $57.50 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 38,012 contracts, representing approximately 3.8 million underlying shares or approximately 43.1% of ABBV's average daily trading volume over the... |
23,615 | 2022-02-10 00:00:00 UTC | The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-abbvie-the-boeing-company-infosys-limited-ford-motor | null | null | For Immediate Release
Chicago, IL – February 10, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, The Boe... | (You can read the full research report on AbbVie here >>>) Boeing shares have gained +6% in the year to date period against the Zacks Aerospace & Defense industry’s rise of +3.2%. Stocks recently featured in the blog include: AbbVie Inc. ABBV, The Boeing Company BA, Infosys Limited INFY, Ford Motor Company F and Public... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, The Boeing Company BA, Infosys Limited INFY, Ford Motor Company F and Public Storage PSA. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., The Boeing Company, and Infosys Limited. Here are highlights from Wedn... | Here are highlights from Wednesday’s Analyst Blog: Top Analyst Reports for AbbVie, Boeing and Infosys The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., The Boeing Company, and Infosys Limited. S... | The Zacks analyst believes that AbbVie has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. Stocks recently featured in the blog include: AbbVie Inc. ABBV, The Boeing Company BA, Infosys Limited INFY, Ford Motor Company F and Public Storage PSA. ... |
23,616 | 2022-02-10 00:00:00 UTC | Interesting ABBV Put And Call Options For April 14th | ABBV | https://www.nasdaq.com/articles/interesting-abbv-put-and-call-options-for-april-14th | null | null | Investors in AbbVie Inc (Symbol: ABBV) saw new options begin trading today, for the April 14th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 14th contracts and identified one put and one call contract of particular interest.
The put contract... | Of course, a lot of upside could potentially be left on the table if ABBV shares really soar, which is why looking at the trailing twelve month trading history for AbbVie Inc, as well as studying the business fundamentals becomes important. Below is a chart showing ABBV's trailing twelve month trading history, with the... | Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Considering the fact that the $145.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the pos... | Below is a chart showing the trailing twelve month trading history for AbbVie Inc, and highlighting in green where the $140.00 strike is located relative to that history: Turning to the calls side of the option chain, the call contract at the $145.00 strike price has a current bid of $3.50. Below is a chart showing ABB... | At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new April 14th contracts and identified one put and one call contract of particular interest. Below is a chart showing ABBV's trailing twelve month trading history, with the $145.00 strike highlighted in red: Consider... |
23,617 | 2022-02-09 00:00:00 UTC | Abbvie Inc Shares Approach 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-approach-52-week-high-market-mover-4 | null | null | Abbvie Inc (ABBV) shares closed today at 0.3% below its 52 week high of $143.60, giving the company a market cap of $253B. The stock is currently up 7.1% year-to-date, up 40.6% over the past 12 months, and up 198.5% over the past five years. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 fell 0.... | Abbvie Inc (ABBV) shares closed today at 0.3% below its 52 week high of $143.60, giving the company a market cap of $253B. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 fell 0.4%. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. | Abbvie Inc (ABBV) shares closed today at 0.3% below its 52 week high of $143.60, giving the company a market cap of $253B. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 fell 0.4%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 0.3% below its 52 week high of $143.60, giving the company a market cap of $253B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.3% below its 52 week high of $143.60, giving the company a market cap of $253B. This week, the Dow Jones Industrial Average rose 0.2%, and the S&P 500 fell 0.4%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,618 | 2022-02-09 00:00:00 UTC | Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up | ABBV | https://www.nasdaq.com/articles/amgen-amgn-provides-strong-long-term-outlook-shares-up | null | null | Amgen AMGN announced an attractive outlook for the company’s business through the end of this decade. Amgen estimates its revenues to increase by mid-single-digit percentage points every year till 2030. The adjusted earnings are expected to exhibit a compound annual growth rate in the range of high single-digit to low ... | Loss of exclusivity for one of the leading revenue generators — AbbVie’s ABBV Humira — in 2023 presents a significant opportunity for Amgen’s biosimilar drug refrencing Humira — Amjevita. We note that AbbVie has garnered more than $16 billion from the United States in 2021 from the sales of Humira. AbbVie Inc. (ABBV): ... | Loss of exclusivity for one of the leading revenue generators — AbbVie’s ABBV Humira — in 2023 presents a significant opportunity for Amgen’s biosimilar drug refrencing Humira — Amjevita. We note that AbbVie has garnered more than $16 billion from the United States in 2021 from the sales of Humira. AbbVie Inc. (ABBV): ... | Loss of exclusivity for one of the leading revenue generators — AbbVie’s ABBV Humira — in 2023 presents a significant opportunity for Amgen’s biosimilar drug refrencing Humira — Amjevita. We note that AbbVie has garnered more than $16 billion from the United States in 2021 from the sales of Humira. AbbVie Inc. (ABBV): ... | Loss of exclusivity for one of the leading revenue generators — AbbVie’s ABBV Humira — in 2023 presents a significant opportunity for Amgen’s biosimilar drug refrencing Humira — Amjevita. We note that AbbVie has garnered more than $16 billion from the United States in 2021 from the sales of Humira. AbbVie Inc. (ABBV): ... |
23,619 | 2022-02-08 00:00:00 UTC | 3 Top Healthcare Stocks to Buy for February | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-to-buy-for-february | null | null | According to Verified Market Research, the global healthcare industry is worth $3.3 trillion today and could grow to $6.6 trillion by 2028. So you might want to consider having healthcare stocks in your portfolio, especially if you're a long-term investor.
The good news is that these companies come in all sorts of flav... | AbbVie's dividend yield is 4%, beating most bonds and savings account rates, and has also been raised aggressively by management, growing an average of 18% annually over the past five years. If AbbVie's emerging drug products can eventually make up most of Humira's losses, the current valuation could be a great entry p... | High dividend yield stock: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that makes prescription products, including Botox and Humira (the world's top-selling drug). AbbVie's nearly $250 billion market cap makes it one of the pharmaceutical industry's biggest companies. AbbVie has an extensive pipeline that gi... | High dividend yield stock: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that makes prescription products, including Botox and Humira (the world's top-selling drug). AbbVie's nearly $250 billion market cap makes it one of the pharmaceutical industry's biggest companies. AbbVie has an extensive pipeline that gi... | This combination of yield and growth makes AbbVie a dividend investor's potential dream stock. High dividend yield stock: AbbVie AbbVie (NYSE: ABBV) is a pharmaceutical company that makes prescription products, including Botox and Humira (the world's top-selling drug). AbbVie's nearly $250 billion market cap makes it o... |
23,620 | 2022-02-08 00:00:00 UTC | Allergan Aesthetics: FDA Approves JUVÉDERM VOLBELLA XC For Improvement Of Infraorbital Hollows | ABBV | https://www.nasdaq.com/articles/allergan-aesthetics%3A-fda-approves-juvederm-volbella-xc-for-improvement-of-infraorbital | null | null | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21. JUVÉDERM VOLBELLA XC was first approved in 2016 for use in the lips and perioral rhytids. The latest approval marks the sixth approved indic... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21. The eye area, including the undereye hollow, is a top concern among patients," said Carrie Strom, President, Global Allergan Aesthetics and ... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21. The eye area, including the undereye hollow, is a top concern among patients," said Carrie Strom, President, Global Allergan Aesthetics and ... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21. The eye area, including the undereye hollow, is a top concern among patients," said Carrie Strom, President, Global Allergan Aesthetics and ... | (RTTNews) - Allergan Aesthetics, an AbbVie company (ABBV), announced the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21. The eye area, including the undereye hollow, is a top concern among patients," said Carrie Strom, President, Global Allergan Aesthetics and ... |
23,621 | 2022-02-07 00:00:00 UTC | Notable ETF Inflow Detected - IWF, ADBE, ABBV, AVGO | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-iwf-adbe-abbv-avgo | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 1000 Growth ETF (Symbol: IWF) where we have detected an approximate $317.5 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 254,450,0... | Among the largest underlying components of IWF, in trading today Adobe Inc (Symbol: ADBE) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Broadcom Inc (Symbol: AVGO) is higher by about 0.4%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IWF, in trading today Adobe Inc (Symbol: ADBE) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Broadcom Inc (Symbol: AVGO) is higher by about 0.4%. For a complete list of holdings, visit the IWF Holdings page » The chart below shows the one year price perfo... | Among the largest underlying components of IWF, in trading today Adobe Inc (Symbol: ADBE) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Broadcom Inc (Symbol: AVGO) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... | Among the largest underlying components of IWF, in trading today Adobe Inc (Symbol: ADBE) is down about 0.1%, AbbVie Inc (Symbol: ABBV) is up about 0.4%, and Broadcom Inc (Symbol: AVGO) is higher by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel,... |
23,622 | 2022-02-07 00:00:00 UTC | These 2 Mega-Cap Stalwart Stocks Just Hit All-Time Highs | ABBV | https://www.nasdaq.com/articles/these-2-mega-cap-stalwart-stocks-just-hit-all-time-highs | null | null | The stock market had another up-and-down day on Monday, as investors tried to get used to volatile conditions. Important questions like whether inflation will prove to be fleeting or how much the Federal Reserve might act to boost interest rates won't get answers in the immediate term. But market participants are still... | Below, we'll take a closer look at what sent Chevron (NYSE: CVX) and AbbVie (NYSE: ABBV) to new heights. AbbVie stays healthy Elsewhere, shares of AbbVie also moved higher, gaining more than 1% on the day. The drugmaker's roughly 37% gains over the past year aren't quite as strong as Chevron's, but AbbVie has plenty of... | AbbVie stays healthy Elsewhere, shares of AbbVie also moved higher, gaining more than 1% on the day. Below, we'll take a closer look at what sent Chevron (NYSE: CVX) and AbbVie (NYSE: ABBV) to new heights. The drugmaker's roughly 37% gains over the past year aren't quite as strong as Chevron's, but AbbVie has plenty of... | Below, we'll take a closer look at what sent Chevron (NYSE: CVX) and AbbVie (NYSE: ABBV) to new heights. AbbVie stays healthy Elsewhere, shares of AbbVie also moved higher, gaining more than 1% on the day. The drugmaker's roughly 37% gains over the past year aren't quite as strong as Chevron's, but AbbVie has plenty of... | AbbVie stays healthy Elsewhere, shares of AbbVie also moved higher, gaining more than 1% on the day. Below, we'll take a closer look at what sent Chevron (NYSE: CVX) and AbbVie (NYSE: ABBV) to new heights. The drugmaker's roughly 37% gains over the past year aren't quite as strong as Chevron's, but AbbVie has plenty of... |
23,623 | 2022-02-07 00:00:00 UTC | Abbvie Inc Shares Near 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-near-52-week-high-market-mover-3 | null | null | Abbvie Inc (ABBV) shares closed today at 0.2% below its 52 week high of $142.80, giving the company a market cap of $248B. The stock is currently up 5.0% year-to-date, up 35.4% over the past 12 months, and up 191.9% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.... | Abbvie Inc (ABBV) shares closed today at 0.2% below its 52 week high of $142.80, giving the company a market cap of $248B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 0.2% below its 52 week high of $142.80, giving the company a market cap of $248B. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Abbvie Inc (ABBV) shares closed today at 0.2% below its 52 week high of $142.80, giving the company a market cap of $248B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.2% below its 52 week high of $142.80, giving the company a market cap of $248B. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
23,624 | 2022-02-07 00:00:00 UTC | Does AbbVie (NYSE:ABBV) Have A Healthy Balance Sheet? | ABBV | https://www.nasdaq.com/articles/does-abbvie-nyse%3Aabbv-have-a-healthy-balance-sheet | null | null | The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how ris... | Our View The good news is that AbbVie's demonstrated ability to convert EBIT to free cash flow delights us like a fluffy puppy does a toddler. We can see that AbbVie Inc. (NYSE:ABBV) does use debt in its business. How Much Debt Does AbbVie Carry? | According to the last reported balance sheet, AbbVie had liabilities of US$28.5b due within 12 months, and liabilities of US$106.7b due beyond 12 months. We can see that AbbVie Inc. (NYSE:ABBV) does use debt in its business. How Much Debt Does AbbVie Carry? | We can see that AbbVie Inc. (NYSE:ABBV) does use debt in its business. How Much Debt Does AbbVie Carry? The image below, which you can click on for greater detail, shows that AbbVie had debt of US$80.7b at the end of September 2021, a reduction from US$86.1b over a year. | We can see that AbbVie Inc. (NYSE:ABBV) does use debt in its business. How Much Debt Does AbbVie Carry? The image below, which you can click on for greater detail, shows that AbbVie had debt of US$80.7b at the end of September 2021, a reduction from US$86.1b over a year. |
23,625 | 2022-02-07 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, Merck, Eli Lilly, Novartis and Pfizer | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-merck-eli-lilly-novartis-and-pfizer | null | null | For Immediate Release
Chicago, IL – February 7, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie ABBV, Merck MRK, El... | Stocks recently featured in the blog include: AbbVie ABBV, Merck MRK, Eli Lilly LLY, Novartis NVS and Pfizer PFE. Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Q4 Earnings Edition This week, AbbVie, Merck, Eli Lilly and Novartis announced fourth-quarter and full-year 2021 results. AbbVie’s fourt... | Stocks recently featured in the blog include: AbbVie ABBV, Merck MRK, Eli Lilly LLY, Novartis NVS and Pfizer PFE. Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Q4 Earnings Edition This week, AbbVie, Merck, Eli Lilly and Novartis announced fourth-quarter and full-year 2021 results. AbbVie’s fourt... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Q4 Earnings Edition This week, AbbVie, Merck, Eli Lilly and Novartis announced fourth-quarter and full-year 2021 results. In the past six months, AbbVie has recorded the maximum gain (25%), while Lilly declined the most (6.8%) (See the last pharma st... | Here are highlights from Friday’s Analyst Blog: Pharma Stock Roundup: Q4 Earnings Edition This week, AbbVie, Merck, Eli Lilly and Novartis announced fourth-quarter and full-year 2021 results. Stocks recently featured in the blog include: AbbVie ABBV, Merck MRK, Eli Lilly LLY, Novartis NVS and Pfizer PFE. AbbVie’s fourt... |
23,626 | 2022-02-05 00:00:00 UTC | Could This New Indication Create a Blockbuster for Pfizer? | ABBV | https://www.nasdaq.com/articles/could-this-new-indication-create-a-blockbuster-for-pfizer | null | null | In mid-January, Pfizer (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) gave the nod to Cibinqo as a treatment for patients with moderate to severe atopic dermatitis (eczema) whose disease wasn't adequately controlled with other treatments.
Why did the FDA approve Cibinqo for moderate to severe ec... | Since there are other drugs on the market like Sanofi and Regeneron's Dupixent and AbbVie's Rinvoq, I'll conservatively assume that Cibinqo can start by capturing 5% of these patients, or 66,000 individuals. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Kody Kester owns AbbVie and Pfizer. The good new... | Since there are other drugs on the market like Sanofi and Regeneron's Dupixent and AbbVie's Rinvoq, I'll conservatively assume that Cibinqo can start by capturing 5% of these patients, or 66,000 individuals. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Kody Kester owns AbbVie and Pfizer. Why did the ... | Since there are other drugs on the market like Sanofi and Regeneron's Dupixent and AbbVie's Rinvoq, I'll conservatively assume that Cibinqo can start by capturing 5% of these patients, or 66,000 individuals. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Kody Kester owns AbbVie and Pfizer. In mid-Janua... | Since there are other drugs on the market like Sanofi and Regeneron's Dupixent and AbbVie's Rinvoq, I'll conservatively assume that Cibinqo can start by capturing 5% of these patients, or 66,000 individuals. See the 10 stocks *Stock Advisor returns as of January 10, 2022 Kody Kester owns AbbVie and Pfizer. And what cou... |
23,627 | 2022-02-05 00:00:00 UTC | Is AbbVie Stock a Buy Now? | ABBV | https://www.nasdaq.com/articles/is-abbvie-stock-a-buy-now-0 | null | null | Drugmaker AbbVie (NYSE: ABBV) has historically been a safe, market-beating stock to own. Over the past five years, its total returns (which include dividend income) of 191% have eclipsed the S&P 500, which has increased by 113% when factoring in its distributions.
But there have been question marks about the future of ... | Drugmaker AbbVie (NYSE: ABBV) has historically been a safe, market-beating stock to own. But there have been question marks about the future of AbbVie, especially with the company losing patent protection for its top-selling drug, Humira, next year. Should investors be worried about the stock, or is AbbVie likely to co... | AbbVie also anticipates that it will generate $24 billion in adjusted free cash flow during the year, which it will use to pay down debt, invest into its already robust pipeline (which features more than a dozen late-stage trials), and support its dividend, which has doubled in just five years. Drugmaker AbbVie (NYSE: ... | AbbVie also anticipates that it will generate $24 billion in adjusted free cash flow during the year, which it will use to pay down debt, invest into its already robust pipeline (which features more than a dozen late-stage trials), and support its dividend, which has doubled in just five years. Drugmaker AbbVie (NYSE: ... | Drugmaker AbbVie (NYSE: ABBV) has historically been a safe, market-beating stock to own. But there have been question marks about the future of AbbVie, especially with the company losing patent protection for its top-selling drug, Humira, next year. Should investors be worried about the stock, or is AbbVie likely to co... |
23,628 | 2022-02-04 00:00:00 UTC | Abbvie Inc Shares Approach 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-approach-52-week-high-market-mover-3 | null | null | Abbvie Inc (ABBV) shares closed today at 0.7% below its 52 week high of $141.71, giving the company a market cap of $248B. The stock is currently up 5.0% year-to-date, up 37.7% over the past 12 months, and up 192.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.8%, and the S&P 500 rose 3.... | Abbvie Inc (ABBV) shares closed today at 0.7% below its 52 week high of $141.71, giving the company a market cap of $248B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.4. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-y... | Abbvie Inc (ABBV) shares closed today at 0.7% below its 52 week high of $141.71, giving the company a market cap of $248B. This week, the Dow Jones Industrial Average rose 2.8%, and the S&P 500 rose 3.6%. The stock closed at 1.3% higher than its 5-day moving average, 3.5% higher than its 20-day moving average, and 14.7... | Abbvie Inc (ABBV) shares closed today at 0.7% below its 52 week high of $141.71, giving the company a market cap of $248B. The stock closed at 1.3% higher than its 5-day moving average, 3.5% higher than its 20-day moving average, and 14.7% higher than its 90-day moving average. Market Comparative Performance The compan... | Abbvie Inc (ABBV) shares closed today at 0.7% below its 52 week high of $141.71, giving the company a market cap of $248B. Trading Activity Trading volume this week was 14.8% higher than the 20-day average. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought... |
23,629 | 2022-02-04 00:00:00 UTC | Viatris (VTRS) Gets FDA Nod for Generic Drug in Dry Eye Disease | ABBV | https://www.nasdaq.com/articles/viatris-vtrs-gets-fda-nod-for-generic-drug-in-dry-eye-disease | null | null | Viatris VTRS announced that the FDA has approved the abbreviated new drug application filed by Mylan Pharmaceuticals, a subsidiary of Viatris, which sought approval for a generic version of Restasis (cyclosporine ophthalmic emulsion 0.05%).
We note that Restasis was initially developed by Allergan, an AbbVie ABBV compa... | We note that Restasis was initially developed by Allergan, an AbbVie ABBV company, to increase the natural ability of eyes to produce tears in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (commonly known as dry eye). In May 2020, AbbVi... | We note that Restasis was initially developed by Allergan, an AbbVie ABBV company, to increase the natural ability of eyes to produce tears in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (commonly known as dry eye). In May 2020, AbbVi... | We note that Restasis was initially developed by Allergan, an AbbVie ABBV company, to increase the natural ability of eyes to produce tears in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca (commonly known as dry eye). In May 2020, AbbVi... | AbbVie Inc. (ABBV): Free Stock Analysis Report We note that Restasis was initially developed by Allergan, an AbbVie ABBV company, to increase the natural ability of eyes to produce tears in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca ... |
23,630 | 2022-02-04 00:00:00 UTC | Pharma Stock Roundup: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-mrk-lly-abbv-post-q4-earnings-pfe-ends-vupanorsen-program | null | null | This week, AbbVie ABBV, Merck MRK, Eli Lilly LLY and Novartis NVS announced fourth-quarter and full-year 2021 results. Pfizer PFE stopped clinical development of vupanorsen, which was being evaluated in cardiovascular risk reduction and severe hypertriglyceridemia indications and returned development rights to partner ... | This week, AbbVie ABBV, Merck MRK, Eli Lilly LLY and Novartis NVS announced fourth-quarter and full-year 2021 results. AbbVie’s fourth-quarter results were mixed as it beat estimates for earnings while missing the same for sales. AbbVie issued EPS guidance for 2022. | This week, AbbVie ABBV, Merck MRK, Eli Lilly LLY and Novartis NVS announced fourth-quarter and full-year 2021 results. AbbVie’s fourth-quarter results were mixed as it beat estimates for earnings while missing the same for sales. AbbVie issued EPS guidance for 2022. | This week, AbbVie ABBV, Merck MRK, Eli Lilly LLY and Novartis NVS announced fourth-quarter and full-year 2021 results. AbbVie’s fourth-quarter results were mixed as it beat estimates for earnings while missing the same for sales. AbbVie issued EPS guidance for 2022. | This week, AbbVie ABBV, Merck MRK, Eli Lilly LLY and Novartis NVS announced fourth-quarter and full-year 2021 results. AbbVie’s fourth-quarter results were mixed as it beat estimates for earnings while missing the same for sales. AbbVie issued EPS guidance for 2022. |
23,631 | 2022-02-03 00:00:00 UTC | AbbVie (ABBV) Q4 2021 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q4-2021-earnings-call-transcript | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q4 2021 Earnings Call
Feb 02, 2022, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie fourth quarter 2021earnings conference call [Operator instr... | AbbVie (NYSE: ABBV) Q4 2021 Earnings Call Feb 02, 2022, 9:00 a.m. Welcome to the AbbVie fourth quarter 2021earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president, head of investor relations. AbbVie cautions that these forward-looking statements are subject to risks a... | Notable opportunities from our mid- to late-stage oncology pipeline include: navitoclax for myelofibrosis, which has the potential to provide disease modification in a market where current treatments only address symptoms; epcoritamab, a potentially best-in-class CD3xCD20 for B-cell malignancies, including DLBCL and fo... | Operator [Operator signoff] Duration: 87 minutes Call participants: Liz Shea -- Vice President and Head of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial Officer Mike Severino -- Vice Chairman and President, Research and D... | Operator [Operator signoff] Duration: 87 minutes Call participants: Liz Shea -- Vice President and Head of Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Chief Commercial Officer Mike Severino -- Vice Chairman and President, Research and D... |
23,632 | 2022-02-02 00:00:00 UTC | 5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV | ABBV | https://www.nasdaq.com/articles/5-top-stock-trades-for-thursday%3A-amd-nvda-fb-qcom-abbv | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
We’re in the thick of earnings season, with more big reports due up after the close and again on Thursday. With that in mind, let’s look at a few top stock trades going into the back-half of the week.
Top Stock Trades for Tomorrow No. 1: Advanced Micro Devi... | 5: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider Lastly, we have AbbVie (NYSE:ABBV). The post 5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV appeared first on InvestorPlace. | The post 5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV appeared first on InvestorPlace. 5: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider Lastly, we have AbbVie (NYSE:ABBV). | The post 5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV appeared first on InvestorPlace. 5: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider Lastly, we have AbbVie (NYSE:ABBV). | The post 5 Top Stock Trades for Thursday: AMD, NVDA, FB, QCOM, ABBV appeared first on InvestorPlace. 5: AbbVie (ABBV) Click to Enlarge Source: Chart courtesy of TrendSpider Lastly, we have AbbVie (NYSE:ABBV). |
23,633 | 2022-02-02 00:00:00 UTC | AbbVie Q4 21 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q4-21-earnings-conference-call-at-9%3A00-am-et | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 2, 2022, to discuss Q4 21 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 2, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 2, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 2, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on February 2, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do ... |
23,634 | 2022-02-02 00:00:00 UTC | U.S. FDA approves first generic form of AbbVie's eye drug | ABBV | https://www.nasdaq.com/articles/u.s.-fda-approves-first-generic-form-of-abbvies-eye-drug-0 | null | null | Adds background, details on drug
Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome.
The condition, which affects millions of Americans every year, occurs whe... | AbbVie and Viatris did not immediately respond to Reuters' requests for comment. Adds background, details on drug Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye sy... | Adds background, details on drug Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome. AbbVie and Viatris did not immediately respond to Reuters' requests for c... | Adds background, details on drug Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome. AbbVie and Viatris did not immediately respond to Reuters' requests for c... | Adds background, details on drug Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome. AbbVie and Viatris did not immediately respond to Reuters' requests for c... |
23,635 | 2022-02-02 00:00:00 UTC | Noteworthy Wednesday Option Activity: ABBV, ORCL, QRVO | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-abbv-orcl-qrvo | null | null | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 39,971 contracts have traded so far, representing approximately 4.0 million underlying shares. That amounts to about 47.3% of ABBV's average daily trading volume over the p... | Particularly high volume was seen for the $145 strike call option expiring March 18, 2022, with 5,391 contracts trading so far today, representing approximately 539,100 underlying shares of ABBV. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ... | Below is a chart showing ABBV's trailing twelve month trading history, with the $145 strike highlighted in orange: Oracle Corp (Symbol: ORCL) options are showing a volume of 46,659 contracts thus far today. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie In... | Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 39,971 contracts have traded so far, representing approximately 4.0 million underlying shares. That amounts to about 47.3% of ABBV's average daily trading volume over the p... | Below is a chart showing QRVO's trailing twelve month trading history, with the $150 strike highlighted in orange: For the various different available expirations for ABBV options, ORCL options, or QRVO options, visit StockOptionsChannel.com. Among the underlying components of the S&P 500 index, we saw noteworthy optio... |
23,636 | 2022-02-02 00:00:00 UTC | U.S. FDA approves first generic form of AbbVie's eye drug | ABBV | https://www.nasdaq.com/articles/u.s.-fda-approves-first-generic-form-of-abbvies-eye-drug | null | null | Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome.
The regulator has given the approval to Mylan Pharmaceuticals Inc.
(Reporting by Amruta Khandekar; Editing... | Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome. The regulator has given the approval to Mylan Pharmaceuticals Inc. (Reporting by Amruta Khandekar; Editing... | Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome. The regulator has given the approval to Mylan Pharmaceuticals Inc. (Reporting by Amruta Khandekar; Editing... | Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome. The regulator has given the approval to Mylan Pharmaceuticals Inc. (Reporting by Amruta Khandekar; Editing... | Feb 2 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it had approved the first generic version of AbbVie's ABBV.N drug, Restasis, to increase tear production in patients with dry eye syndrome. The regulator has given the approval to Mylan Pharmaceuticals Inc. (Reporting by Amruta Khandekar; Editing... |
23,637 | 2022-02-02 00:00:00 UTC | Abbvie Inc Shares Climb 0.2% Past Previous 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-climb-0.2-past-previous-52-week-high-market-mover | null | null | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $242B. The stock is currently up 2.2% year-to-date, up 40.2% over the past 12 months, and up 183.2% over the past five years. This week, the Dow Jones Industrial Average rose 3.2%, and the S&P 500 rose 4.3%.
T... | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $242B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $242B. This week, the Dow Jones Industrial Average rose 3.2%, and the S&P 500 rose 4.3%. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, ... | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $242B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jo... | Abbvie Inc (ABBV) shares closed 0.2% higher than its previous 52 week high, giving the company a market cap of $242B. This week, the Dow Jones Industrial Average rose 3.2%, and the S&P 500 rose 4.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
23,638 | 2022-02-02 00:00:00 UTC | AbbVie (ABBV) Tops Q4 Earnings Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q4-earnings-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $2.92 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.61%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.29 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.89 billion for the quarter ended December 2021, missing the Zacks Consensus Estimate by 0.94%. AbbVie ... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.89 billion for the quarter ended December 2021, missing the Zacks Consensus Estimate by 0.94%. AbbVie (ABBV) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.29 per share. AbbVie ... | AbbVie (ABBV) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.29 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.89 billion for the quarter ended December 2021, missing the Zacks Consensus Estimate by 0.94%. AbbVie ... | AbbVie (ABBV) came out with quarterly earnings of $3.31 per share, beating the Zacks Consensus Estimate of $3.29 per share. While AbbVie has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals i... |
23,639 | 2022-02-02 00:00:00 UTC | AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-q4-earnings-surpass-estimates-sales-miss | null | null | AbbVie Inc. ABBV reported earnings of $3.31 per share for the fourth quarter of 2021, beating the Zacks Consensus Estimate of $3.29 and exceeding the guided range of $3.24 to $3.28 per share. Earnings rose 13.4% year over year.
The company’s revenues of $14.89 billion slightly missed the Zacks Consensus Estimate of $15... | AbbVie Inc. ABBV reported earnings of $3.31 per share for the fourth quarter of 2021, beating the Zacks Consensus Estimate of $3.29 and exceeding the guided range of $3.24 to $3.28 per share. Shares of AbbVie were up 1% in pre-market trading on the earnings beat. AbbVie’s shares have gained 32.4% in the past year compa... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales rose 4.7% on an operational basis to $1.87 billion in the quarter, driven by the strong growth of Venclexta sales, partially offset by lower U.S. sales of Imbruvica. AbbVie Inc. ABBV reported earnings of $3.31 per share for the fourth quarter of 202... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales rose 4.7% on an operational basis to $1.87 billion in the quarter, driven by the strong growth of Venclexta sales, partially offset by lower U.S. sales of Imbruvica. AbbVie Inc. Price and EPS Surprise AbbVie Inc. price-eps-surprise | AbbVie Inc. Quo... | AbbVie’s oncology/hematology (including Imbruvica and Venclexta) sales rose 4.7% on an operational basis to $1.87 billion in the quarter, driven by the strong growth of Venclexta sales, partially offset by lower U.S. sales of Imbruvica. AbbVie Inc. ABBV reported earnings of $3.31 per share for the fourth quarter of 202... |
23,640 | 2022-02-02 00:00:00 UTC | AbbVie Guides FY22 Adj. EPS Above Estimates - Quick Facts | ABBV | https://www.nasdaq.com/articles/abbvie-guides-fy22-adj.-eps-above-estimates-quick-facts | null | null | (RTTNews) - While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie Inc. (ABBV) initiated its earnings and adjusted earnings guidance for the full-year 2022.
For fiscal 2022, AbbVie now projects earnings in a range of $9.26 to $9.46 per share and adjusted earnings in a ra... | (RTTNews) - While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie Inc. (ABBV) initiated its earnings and adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie now projects earnings in a range of $9.26 to $9.46 per share and adjusted earnings in a ra... | (RTTNews) - While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie Inc. (ABBV) initiated its earnings and adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie now projects earnings in a range of $9.26 to $9.46 per share and adjusted earnings in a ra... | (RTTNews) - While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie Inc. (ABBV) initiated its earnings and adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie now projects earnings in a range of $9.26 to $9.46 per share and adjusted earnings in a ra... | (RTTNews) - While reporting financial results for the fourth quarter on Wednesday, biopharmaceutical company AbbVie Inc. (ABBV) initiated its earnings and adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie now projects earnings in a range of $9.26 to $9.46 per share and adjusted earnings in a ra... |
23,641 | 2022-02-02 00:00:00 UTC | AbbVie forecasts 2022 profit above estimates on strong sales of Botox, Skyrizi | ABBV | https://www.nasdaq.com/articles/abbvie-forecasts-2022-profit-above-estimates-on-strong-sales-of-botox-skyrizi | null | null | Feb 2 (Reuters) - AbbVie Inc ABBV.N forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales.
The company's best-selling drug Humira is expected to face competition from rivals in t... | Feb 2 (Reuters) - AbbVie Inc ABBV.N forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales. Excluding items, AbbVie earned $3.31 per share. The company's best-selling drug Humira ... | Feb 2 (Reuters) - AbbVie Inc ABBV.N forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales. Excluding items, AbbVie earned $3.31 per share. Sales of Humira, which is already facin... | Feb 2 (Reuters) - AbbVie Inc ABBV.N forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales. Excluding items, AbbVie earned $3.31 per share. The company's best-selling drug Humira ... | Feb 2 (Reuters) - AbbVie Inc ABBV.N forecast full-year adjusted profit above estimates on Wednesday, as its blockbuster anti-wrinkle injection Botox and newer psoriasis drug Skyrizi beat Wall Street expectations for quarterly sales. Excluding items, AbbVie earned $3.31 per share. The company's best-selling drug Humira ... |
23,642 | 2022-02-02 00:00:00 UTC | AbbVie Q4 Profit Increases, beats estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q4-profit-increases-beats-estimates | null | null | (RTTNews) - AbbVie (ABBV) released earnings for its fourth quarter that increased from last year and beat the Street estimates.
The company's bottom line came in at $4.04 billion, or $2.26 per share. This compares with $36 million, or $0.01 per share, in last year's fourth quarter.
Excluding items, AbbVie reported adju... | (RTTNews) - AbbVie (ABBV) released earnings for its fourth quarter that increased from last year and beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $6.76 billion or $3.31 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $4.04 Bln. | Excluding items, AbbVie reported adjusted earnings of $6.76 billion or $3.31 per share for the period. (RTTNews) - AbbVie (ABBV) released earnings for its fourth quarter that increased from last year and beat the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $4.04 Bln. | (RTTNews) - AbbVie (ABBV) released earnings for its fourth quarter that increased from last year and beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $6.76 billion or $3.31 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $4.04 Bln. | (RTTNews) - AbbVie (ABBV) released earnings for its fourth quarter that increased from last year and beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $6.76 billion or $3.31 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q4): $4.04 Bln. |
23,643 | 2022-02-01 00:00:00 UTC | Why AbbVie (ABBV) Might Surprise This Earnings Season | ABBV | https://www.nasdaq.com/articles/why-abbvie-abbv-might-surprise-this-earnings-season | null | null | Investors are always looking for stocks that are poised to beat at earnings season and AbbVie Inc. ABBV may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because AbbVie is seeing favorable earnings estimate revision activity as of lat... | After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for ABBV in this report. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this st... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +0.08% heading into earnings season. Investors are always looking for stocks that are poised to beat at earnings season and AbbVie Inc. ABBV may be one such company. That is because AbbVie is seei... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +0.08% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looki... | This suggests that analysts have very recently bumped up their estimates for ABBV, giving the stock a Zacks Earnings ESP of +0.08% heading into earnings season. Given that ABBV has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. Investors are always looki... |
23,644 | 2022-02-01 00:00:00 UTC | AbbVie a Top Socially Responsible Dividend Stock With 4.1% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-a-top-socially-responsible-dividend-stock-with-4.1-yield-abbv | null | null | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... | AbbVie Inc (Symbol: ABBV) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of... |
23,645 | 2022-02-01 00:00:00 UTC | Gilead COVID drug takes top spot for U.S. hospital spending -report | ABBV | https://www.nasdaq.com/articles/gilead-covid-drug-takes-top-spot-for-u.s.-hospital-spending-report | null | null | By Deena Beasley
Feb 1 (Reuters) - Gilead Sciences Inc's GILD.O COVID-19 drug remdesivir last year overtook AbbVie Inc's ABBV.N 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals.
Remdesivir, an ... | By Deena Beasley Feb 1 (Reuters) - Gilead Sciences Inc's GILD.O COVID-19 drug remdesivir last year overtook AbbVie Inc's ABBV.N 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals. Remdesivir, an ... | By Deena Beasley Feb 1 (Reuters) - Gilead Sciences Inc's GILD.O COVID-19 drug remdesivir last year overtook AbbVie Inc's ABBV.N 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals. Remdesivir, an ... | By Deena Beasley Feb 1 (Reuters) - Gilead Sciences Inc's GILD.O COVID-19 drug remdesivir last year overtook AbbVie Inc's ABBV.N 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals. Remdesivir, an ... | By Deena Beasley Feb 1 (Reuters) - Gilead Sciences Inc's GILD.O COVID-19 drug remdesivir last year overtook AbbVie Inc's ABBV.N 20-year-old arthritis drug Humira as the medicine that U.S. hospitals spent the most on, according to Vizient Inc, a purchasing group used by about half the nation's hospitals. Remdesivir, an ... |
23,646 | 2022-02-01 00:00:00 UTC | Pharma Stocks to Report Q4 Earnings on Feb 2: ABBV, NVS & NVO | ABBV | https://www.nasdaq.com/articles/pharma-stocks-to-report-q4-earnings-on-feb-2%3A-abbv-nvs-nvo | null | null | The pharma bellwether, Johnson & Johnson JNJ, marked the beginning of earnings season for pharma/drug/biotech companies from the Medical sector when it reported its fourth-quarter results on Jan 25, 2022. This was followed by fourth-quarter results of large-cap biotech, Vertex Pharmaceuticals, and generic drugmaker, Dr... | The earnings scenario is favorable for the big pharma company, AbbVie ABBV, scheduled to release fourth quarter results on Feb 2. Humira and Botox-owner, AbbVie is scheduled to report before market open. AbbVie delivered a four-quarter earnings surprise of 3.02%, on average. | The earnings scenario is favorable for the big pharma company, AbbVie ABBV, scheduled to release fourth quarter results on Feb 2. Humira and Botox-owner, AbbVie is scheduled to report before market open. AbbVie delivered a four-quarter earnings surprise of 3.02%, on average. | For the quarter to be reported, AbbVie has an Earnings ESP of +0.08% and a Zacks Rank #3, indicating a likely earnings beat. The earnings scenario is favorable for the big pharma company, AbbVie ABBV, scheduled to release fourth quarter results on Feb 2. Humira and Botox-owner, AbbVie is scheduled to report before mark... | For the quarter to be reported, AbbVie has an Earnings ESP of +0.08% and a Zacks Rank #3, indicating a likely earnings beat. AbbVie Inc. (ABBV): Free Stock Analysis Report The earnings scenario is favorable for the big pharma company, AbbVie ABBV, scheduled to release fourth quarter results on Feb 2. |
23,647 | 2022-02-01 00:00:00 UTC | Pre-Market Earnings Report for February 2, 2022 : ABBV, TMO, WM, BSX, EMR, JCI, HUM, ROP, MPC, IDXX, RACE, ODFL | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-february-2-2022-%3A-abbv-tmo-wm-bsx-emr-jci-hum-rop-mpc-idxx | null | null | The following companies are expected to report earnings prior to market open on 02/02/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2021. The large cap pharmaceutical company's consensus earnings per share forecast fr... | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 10.80 vs. an industry ratio of 16.10. | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 10.80 vs. an industry ratio of 16.10. | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 10.80 vs. an industry ratio of 16.10. | AbbVie Inc. (ABBV)is reporting for the quarter ending December 31, 2021. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2021 Price to Earnings ratio for ABBV is 10.80 vs. an industry ratio of 16.10. |
23,648 | 2022-02-01 00:00:00 UTC | 5 High-Yield Dividend Stocks That Can Save Your Portfolio During a Stock Market Crash | ABBV | https://www.nasdaq.com/articles/5-high-yield-dividend-stocks-that-can-save-your-portfolio-during-a-stock-market-crash | null | null | January provided a not-so-subtle reminder that stock market crashes and corrections are a normal part of the investing cycle, and they can occur without warning. Both the benchmark S&P 500 and growth stock-driven Nasdaq Composite endured their steepest corrections in close to two years.
While steep moves lower in the m... | AbbVie: 4.1% yield A fifth high-yield dividend stock that can save your portfolio if a market crash strikes is pharmaceutical stock AbbVie (NYSE: ABBV). Although AbbVie's 4% yield pales in comparison to the likes of Annaly, bear in mind that the former's share price has more than doubled over the past 2.5 years. There'... | AbbVie: 4.1% yield A fifth high-yield dividend stock that can save your portfolio if a market crash strikes is pharmaceutical stock AbbVie (NYSE: ABBV). Although AbbVie's 4% yield pales in comparison to the likes of Annaly, bear in mind that the former's share price has more than doubled over the past 2.5 years. There'... | AbbVie: 4.1% yield A fifth high-yield dividend stock that can save your portfolio if a market crash strikes is pharmaceutical stock AbbVie (NYSE: ABBV). Although AbbVie's 4% yield pales in comparison to the likes of Annaly, bear in mind that the former's share price has more than doubled over the past 2.5 years. There'... | AbbVie: 4.1% yield A fifth high-yield dividend stock that can save your portfolio if a market crash strikes is pharmaceutical stock AbbVie (NYSE: ABBV). Although AbbVie's 4% yield pales in comparison to the likes of Annaly, bear in mind that the former's share price has more than doubled over the past 2.5 years. There'... |
23,649 | 2022-02-01 00:00:00 UTC | 3 Warren Buffett Dividend Stocks to Buy in February | ABBV | https://www.nasdaq.com/articles/3-warren-buffett-dividend-stocks-to-buy-in-february | null | null | Warren Buffett has given Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) shareholders a lot through the years. Most importantly, under his direction, Berkshire has handily beaten the market.
However, there's one thing that Oracle of Omaha hasn't given Berkshire shareholders -- a dividend. That doesn't mean that Buffett ... | Keith Speights owns AbbVie, Bank of America, and Berkshire Hathaway (B shares). AbbVie AbbVie (NYSE: ABBV) offers one of the juiciest dividends of all the stocks in Berkshire's portfolio with a yield north of 4.1%. AbbVie ranks as a Dividend Aristocrat with 49 consecutive years of dividend increases. | AbbVie AbbVie (NYSE: ABBV) offers one of the juiciest dividends of all the stocks in Berkshire's portfolio with a yield north of 4.1%. AbbVie ranks as a Dividend Aristocrat with 49 consecutive years of dividend increases. Buffett almost certainly also likes AbbVie's valuation. | AbbVie AbbVie (NYSE: ABBV) offers one of the juiciest dividends of all the stocks in Berkshire's portfolio with a yield north of 4.1%. AbbVie ranks as a Dividend Aristocrat with 49 consecutive years of dividend increases. Buffett almost certainly also likes AbbVie's valuation. | AbbVie AbbVie (NYSE: ABBV) offers one of the juiciest dividends of all the stocks in Berkshire's portfolio with a yield north of 4.1%. AbbVie ranks as a Dividend Aristocrat with 49 consecutive years of dividend increases. Buffett almost certainly also likes AbbVie's valuation. |
23,650 | 2022-02-01 00:00:00 UTC | 3 Pharmaceutical Stocks With Dividend Yields of 2.9% or Better | ABBV | https://www.nasdaq.com/articles/3-pharmaceutical-stocks-with-dividend-yields-of-2.9-or-better | null | null | Nervous investors have been selling risky growth stocks in favor of profit-generating businesses that pay steady dividends. The pharmaceutical industry is one area of the stock market that dividend-seeking investors haven't rushed into yet which means some reliably profitable big pharma companies are offering above-ave... | AbbVie It's been a lousy year for growth stocks, but not steadily profitable dividend payers like AbbVie (NYSE: ABBV). AbbVie's raised its dividend by a whopping 120% over the past five years thanks to strong sales of its lead drug Humira. First approved by the FDA in 2002, this treatment for rheumatoid arthritis and p... | AbbVie It's been a lousy year for growth stocks, but not steadily profitable dividend payers like AbbVie (NYSE: ABBV). AbbVie's raised its dividend by a whopping 120% over the past five years thanks to strong sales of its lead drug Humira. First approved by the FDA in 2002, this treatment for rheumatoid arthritis and p... | AbbVie It's been a lousy year for growth stocks, but not steadily profitable dividend payers like AbbVie (NYSE: ABBV). AbbVie's raised its dividend by a whopping 120% over the past five years thanks to strong sales of its lead drug Humira. First approved by the FDA in 2002, this treatment for rheumatoid arthritis and p... | AbbVie It's been a lousy year for growth stocks, but not steadily profitable dividend payers like AbbVie (NYSE: ABBV). AbbVie's raised its dividend by a whopping 120% over the past five years thanks to strong sales of its lead drug Humira. First approved by the FDA in 2002, this treatment for rheumatoid arthritis and p... |
23,651 | 2022-02-01 00:00:00 UTC | Abbvie Inc Shares Approach 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-approach-52-week-high-market-mover-2 | null | null | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $138.30, giving the company a market cap of $241B. The stock is currently up 2.1% year-to-date, up 39.8% over the past 12 months, and up 182.0% over the past five years. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.... | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $138.30, giving the company a market cap of $241B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $138.30, giving the company a market cap of $241B. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 22.2% higher than the 20-day average. | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $138.30, giving the company a market cap of $241B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.9% below its 52 week high of $138.30, giving the company a market cap of $241B. This week, the Dow Jones Industrial Average rose 2.1%, and the S&P 500 rose 2.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
23,652 | 2022-01-31 00:00:00 UTC | Bristol-Myers (BMY) to Post Q4 Earnings: What's in Store? | ABBV | https://www.nasdaq.com/articles/bristol-myers-bmy-to-post-q4-earnings%3A-whats-in-store | null | null | Bristol-Myers Squibb Company BMY is scheduled to report fourth-quarter 2021 results on Feb 4, before market open.
The company’s shares have gained 4.3% in the past year against the industry's decline of 38.8%.
Image Source: Zacks Investment Research
Bristol-Myers has had a pretty decent track record, beating earnings e... | AbbVie ABBV has an Earnings ESP of +0.08% and a Zacks Rank #3. AbbVie topped earnings estimates in each of the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. | AbbVie ABBV has an Earnings ESP of +0.08% and a Zacks Rank #3. AbbVie topped earnings estimates in each of the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. | AbbVie ABBV has an Earnings ESP of +0.08% and a Zacks Rank #3. AbbVie topped earnings estimates in each of the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. | AbbVie topped earnings estimates in each of the past four quarters. AbbVie ABBV has an Earnings ESP of +0.08% and a Zacks Rank #3. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. |
23,653 | 2022-01-31 00:00:00 UTC | AbbVie's (ABBV) Q4 Earnings May Reflect Slower Sales Recovery | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-q4-earnings-may-reflect-slower-sales-recovery | null | null | AbbVie, Inc.’s ABBV fourth-quarter results are likely to reflect the impact of the recovering trend in drug sales being observed since the second quarter of 2021. The majority of the company’s drugs, especially the aesthetics franchise, witnessed a strong recovery in the past two quarters. However, in certain disease a... | AbbVie, Inc.’s ABBV fourth-quarter results are likely to reflect the impact of the recovering trend in drug sales being observed since the second quarter of 2021. AbbVie’s stock has gained 34.8% in the past year compared with an increase of 17.5% for the industry. We expect fourth-quarter sales growth to be muted for t... | AbbVie, Inc.’s ABBV fourth-quarter results are likely to reflect the impact of the recovering trend in drug sales being observed since the second quarter of 2021. AbbVie’s stock has gained 34.8% in the past year compared with an increase of 17.5% for the industry. We expect fourth-quarter sales growth to be muted for t... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. price-eps-surprise | AbbVie Inc. Quote Zacks Rank & Stock to Consider AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie, Inc.’s ABBV fourth-quarter results are likely to reflect the impact of the recovering trend in drug sales being observed since the second quarter ... | AbbVie, Inc.’s ABBV fourth-quarter results are likely to reflect the impact of the recovering trend in drug sales being observed since the second quarter of 2021. AbbVie’s stock has gained 34.8% in the past year compared with an increase of 17.5% for the industry. We expect fourth-quarter sales growth to be muted for t... |
23,654 | 2022-01-31 00:00:00 UTC | Zacks Investment Ideas feature highlights: Bank of America, AbbVie, and Microsoft | ABBV | https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-bank-of-america-abbvie-and-microsoft | null | null | For Immediate Release
Chicago, IL – January 31, 2022 – Today, Zacks Investment Ideas features: Bank of America BAC, AbbVie ABBV, and Microsoft MSFT.
Value, Growth or Momentum: What Kind of Investor Are You?
The Covid-19 pandemic impacted all of us in many different ways. From work to family to finances, we were forced ... | For Immediate Release Chicago, IL – January 31, 2022 – Today, Zacks Investment Ideas features: Bank of America BAC, AbbVie ABBV, and Microsoft MSFT. AbbVie: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cy... | For Immediate Release Chicago, IL – January 31, 2022 – Today, Zacks Investment Ideas features: Bank of America BAC, AbbVie ABBV, and Microsoft MSFT. AbbVie: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cy... | For Immediate Release Chicago, IL – January 31, 2022 – Today, Zacks Investment Ideas features: Bank of America BAC, AbbVie ABBV, and Microsoft MSFT. AbbVie: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cy... | For Immediate Release Chicago, IL – January 31, 2022 – Today, Zacks Investment Ideas features: Bank of America BAC, AbbVie ABBV, and Microsoft MSFT. AbbVie: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cy... |
23,655 | 2022-01-30 00:00:00 UTC | Better Dividend Stock: AbbVie or Pfizer? | ABBV | https://www.nasdaq.com/articles/better-dividend-stock%3A-abbvie-or-pfizer | null | null | The healthcare sector offers income-seeking investors plenty of attractive stocks to consider. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) especially stand out. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these two dividend stocks is the b... | One of the reasons why AbbVie has such a large dividend yield is that investors are expecting a major decline in revenue due to the competition from biosimilars of Humira. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) especially stand out. AbbVie and Pfizer rank as two of the most widely followed healthcare dividend stock... | Brian Orelli: AbbVie would seem to have the advantage given its dividend yield of 3.9 percent, Pfizer's dividend yields only 2.9 percent. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) especially stand out. AbbVie and Pfizer rank as two of the most widely followed healthcare dividend stocks. | AbbVie and Pfizer rank as two of the most widely followed healthcare dividend stocks. Brian Orelli: AbbVie would seem to have the advantage given its dividend yield of 3.9 percent, Pfizer's dividend yields only 2.9 percent. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) especially stand out. | Brian, which of these two -- AbbVie or Pfizer -- do you think is the better choice for income investors and why? AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) especially stand out. AbbVie and Pfizer rank as two of the most widely followed healthcare dividend stocks. |
23,656 | 2022-01-29 00:00:00 UTC | Can AbbVie Beat Pfizer in the Atopic Dermatitis Market? | ABBV | https://www.nasdaq.com/articles/can-abbvie-beat-pfizer-in-the-atopic-dermatitis-market | null | null | Both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) recently picked up regulatory approvals for JAK inhibitors for treating atopic dermatitis. In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether AbbVie is likely to beat Pfizer in this large market.
10... | In addition to Pfizer winning a green light for abrocitinib, AbbVie gained FDA approval for its JAK inhibitor, Rinvoq, in that same indication. Both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) recently picked up regulatory approvals for JAK inhibitors for treating atopic dermatitis. In this Motley Fool Live video record... | In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether AbbVie is likely to beat Pfizer in this large market. In addition to Pfizer winning a green light for abrocitinib, AbbVie gained FDA approval for its JAK inhibitor, Rinvoq, in that same indicatio... | In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether AbbVie is likely to beat Pfizer in this large market. Both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) recently picked up regulatory approvals for JAK inhibitors for treating atopic dermatitis. 10... | In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether AbbVie is likely to beat Pfizer in this large market. AbbVie's Rinvoq appears to have maybe slightly better efficacy than Pfizer's Cibinqo. Both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) recentl... |
23,657 | 2022-01-28 00:00:00 UTC | Value, Growth, or Momentum: What Kind of Investor are You? | ABBV | https://www.nasdaq.com/articles/value-growth-or-momentum%3A-what-kind-of-investor-are-you | null | null | The Covid-19 pandemic impacted all of us in many different ways. From work to family to finances, we were forced to adapt to a “new normal” that included staying home, jumping on Zoom calls, doing puzzles, and baking a ton of sourdough bread (or was that just me?).
The coronavirus crisis also likely changed how you inv... | AbbVie ABBV: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cystic fibrosis. Despite Humira’s pending U.S. patent expiration in 2023, ABBV is still generating solid revenue growth and boosting its pipeline ... | AbbVie ABBV: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cystic fibrosis. Despite Humira’s pending U.S. patent expiration in 2023, ABBV is still generating solid revenue growth and boosting its pipeline ... | AbbVie ABBV: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cystic fibrosis. Despite Humira’s pending U.S. patent expiration in 2023, ABBV is still generating solid revenue growth and boosting its pipeline ... | Disclaimer: I own MSFT in my personal portfolio and ABBV in the Income Investor portfolio. AbbVie ABBV: A biopharmaceutical giant, AbbVie is known for its large drug portfolio of treatments for rheumatoid arthritis, Crohn’s disease, hepatitis C, endometriosis, and cystic fibrosis. Despite Humira’s pending U.S. patent e... |
23,658 | 2022-01-28 00:00:00 UTC | Is a Beat Likely for AbbVie (ABBV) This Earnings Season? | ABBV | https://www.nasdaq.com/articles/is-a-beat-likely-for-abbvie-abbv-this-earnings-season | null | null | AbbVie ABBV, slated to report fourth-quarter 2021 results on Feb 2, before market open, is expected to beat expectations. In the last reported quarter, the company delivered an earnings surprise of 3.10%.
AbbVie’s stock has gained 33.4% in the past year compared with an increase of 14.2% for the industry.
Image Source:... | In December, AbbVie updated the Rinvoq label to include boxed warnings about an increased risk of serious heart-related events, cancer, blood clots, and even death following a Drug Safety Communication issued by the FDA in September. AbbVie ABBV, slated to report fourth-quarter 2021 results on Feb 2, before market open... | AbbVie ABBV, slated to report fourth-quarter 2021 results on Feb 2, before market open, is expected to beat expectations. AbbVie’s stock has gained 33.4% in the past year compared with an increase of 14.2% for the industry. AbbVie expects adjusted revenues of approximately $15 billion, indicating year-over-year growth ... | Sales of AbbVie’s new Hepatitis C drug, Mavyret, started recovering from the pandemic impact during the second quarter, which continued in the third quarter. AbbVie Inc. Price and EPS Surprise AbbVie Inc. price-eps-surprise | AbbVie Inc. Quote Another Stock to Consider Here is a large drug stock that has the right comb... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. price-eps-surprise | AbbVie Inc. Quote Another Stock to Consider Here is a large drug stock that has the right combination of elements to beat on earnings this time around: Eli Lilly LLY has an Earnings ESP of +0.20% and a Zacks Rank #2. AbbVie ABBV, slated to report fourt... |
23,659 | 2022-01-28 00:00:00 UTC | Gilead (GILD) to Report Q4 Earnings: Is a Beat in the Cards? | ABBV | https://www.nasdaq.com/articles/gilead-gild-to-report-q4-earnings%3A-is-a-beat-in-the-cards | null | null | Biotech major Gilead Sciences Inc. GILD is slated to report fourth-quarter 2021 results on Feb 1, after market close.
The company has an excellent track record, with earnings beating estimates in all of the last four quarters, the average beat being 15.7%. In the last reported quarter, the company beat expectations by ... | AbbVie ABBV has an Earnings ESP of +0.26% and a Zacks Rank #3. AbbVie has an excellent record and topped earnings estimates in the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. | AbbVie ABBV has an Earnings ESP of +0.26% and a Zacks Rank #3. AbbVie has an excellent record and topped earnings estimates in the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. | AbbVie ABBV has an Earnings ESP of +0.26% and a Zacks Rank #3. AbbVie has an excellent record and topped earnings estimates in the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. | AbbVie ABBV has an Earnings ESP of +0.26% and a Zacks Rank #3. AbbVie has an excellent record and topped earnings estimates in the past four quarters. AbbVie pulled off a four-quarter earnings surprise of 3.02%, on average. |
23,660 | 2022-01-27 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, Edwards Lifesciences and Johnson Controls International | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-edwards-lifesciences-and-johnson-controls | null | null | For Immediate Release
Chicago, IL – January 27, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Edwards ... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls International plc JCI. Here are highlights from Wednesday’s Analyst Blog: Top Analyst Reports for AbbVie, Edwards Lifesciences and Johnson Controls The Zacks Research Daily presents the best research outp... | Stocks recently featured in the blog include: AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls International plc JCI. Here are highlights from Wednesday’s Analyst Blog: Top Analyst Reports for AbbVie, Edwards Lifesciences and Johnson Controls The Zacks Research Daily presents the best research outp... | Here are highlights from Wednesday’s Analyst Blog: Top Analyst Reports for AbbVie, Edwards Lifesciences and Johnson Controls The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc., Edwards Lifescience... | Here are highlights from Wednesday’s Analyst Blog: Top Analyst Reports for AbbVie, Edwards Lifesciences and Johnson Controls The Zacks Research Daily presents the best research output of our analyst team. The Zacks analyst believes that several new drugs in AbbVie’s portfolio have the potential to drive revenues once H... |
23,661 | 2022-01-27 00:00:00 UTC | 2 Stocks to Buy During Market Turbulence Before Earnings | ABBV | https://www.nasdaq.com/articles/2-stocks-to-buy-during-market-turbulence-before-earnings | null | null | The S&P 500 and the Nasdaq last week posted their worst performances since the pandemic began. The benchmark index is officially in correction territory (down 10% or more from its highs) and the tech-heavy Nasdaq is down around 16%.
Both indexes are currently trading beneath their 200-day moving averages for the first ... | ABBV’s deal brought Botox and other popular drugs into a diversified medicine cabinet that includes immunology, oncology, neuroscience, a strong R&D pipeline, and much more. Image Source: Zacks Investment Research AbbVie ABBV – Q4 Financial Results DueWednesday, Feb. 2 AbbVie is prepared for a bright future even as pat... | Image Source: Zacks Investment Research AbbVie ABBV – Q4 Financial Results DueWednesday, Feb. 2 AbbVie is prepared for a bright future even as patent protections run out for one of the world’s best-selling drugs, Humira—biosimilars are available outside of the U.S., with domestic competition to start in 2023. AbbVie re... | Image Source: Zacks Investment Research AbbVie ABBV – Q4 Financial Results DueWednesday, Feb. 2 AbbVie is prepared for a bright future even as patent protections run out for one of the world’s best-selling drugs, Humira—biosimilars are available outside of the U.S., with domestic competition to start in 2023. AbbVie re... | AbbVie Inc. (ABBV): Free Stock Analysis Report Image Source: Zacks Investment Research AbbVie ABBV – Q4 Financial Results DueWednesday, Feb. 2 AbbVie is prepared for a bright future even as patent protections run out for one of the world’s best-selling drugs, Humira—biosimilars are available outside of the U.S., with d... |
23,662 | 2022-01-27 00:00:00 UTC | 2 Dirt-Cheap Dividend Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/2-dirt-cheap-dividend-stocks-to-buy-and-hold-forever | null | null | Dividend stocks are worth serious consideration, especially given the current state of the economy. With inflation near 40-year highs in the U.S., dividends can be a source of supplemental income for those who need it. And since the rise in prices can eat into investors' returns, opting for automatic dividend reinvestm... | Let's look at two companies to consider -- both of which are excellent, dividend-paying companies and look like steals at current levels: AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). AbbVie Pharma giant AbbVie offers a dividend yield of 4.01%, significantly higher than the S&P 500's average of 1.27%. Equal... | Let's look at two companies to consider -- both of which are excellent, dividend-paying companies and look like steals at current levels: AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). AbbVie Pharma giant AbbVie offers a dividend yield of 4.01%, significantly higher than the S&P 500's average of 1.27%. Equal... | Let's look at two companies to consider -- both of which are excellent, dividend-paying companies and look like steals at current levels: AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). AbbVie Pharma giant AbbVie offers a dividend yield of 4.01%, significantly higher than the S&P 500's average of 1.27%. Equal... | Let's look at two companies to consider -- both of which are excellent, dividend-paying companies and look like steals at current levels: AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY). AbbVie Pharma giant AbbVie offers a dividend yield of 4.01%, significantly higher than the S&P 500's average of 1.27%. Equal... |
23,663 | 2022-01-27 00:00:00 UTC | Should Value Investors Pick AbbVie (ABBV) At Present? | ABBV | https://www.nasdaq.com/articles/should-value-investors-pick-abbvie-abbv-at-present | null | null | Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking... | Bottom Line AbbVie is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Let’s put AbbVie ABBV into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewher... | On this front, AbbVie has a trailing twelve months PE ratio of 10.9, as you can see in the chart below: Image Source: Zacks Investment Research This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 22.6. You can see the consensus estimate trend and recent pric... | Let’s put AbbVie ABBV into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. You can see... | Right now, AbbVie has a P/S ratio of about 4.3. Let’s put AbbVie ABBV into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price... |
23,664 | 2022-01-26 00:00:00 UTC | Top Analyst Reports for AbbVie, Edwards Lifesciences & Johnson Controls | ABBV | https://www.nasdaq.com/articles/top-analyst-reports-for-abbvie-edwards-lifesciences-johnson-controls | null | null | Wednesday, January 26, 2022
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls International plc JCI. These research reports have been han... | Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls International plc JCI. You can see all of today’s research reports here >>> Shares of AbbVie have outperformed the Zacks Large-Cap Pharmaceuticals industry over the pa... | Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls International plc JCI. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Pipeline & Ne... | Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. ABBV, Edwards Lifesciences Corp. EW, and Johnson Controls International plc JCI. If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read AbbVie's (ABBV) Pipeline & Ne... | The Zacks analyst believes that several new drugs in AbbVie’s portfolio have the potential to drive revenues once Humira loses U.S. exclusivity in 2023. AbbVie Inc. (ABBV): Free Stock Analysis Report Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. ABBV, Edwards Lifescience... |
23,665 | 2022-01-26 00:00:00 UTC | AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-reports-next-week%3A-wall-street-expects-earnings-growth | null | null | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock p... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have r... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have r... | The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. How Have the Numbers Shaped Up for AbbVie? For AbbVie, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have r... | So, this combination indicates that AbbVie will most likely beat the consensus EPS estimate. For the last reported quarter, it was expected that AbbVie would post earnings of $3.23 per share when it actually produced earnings of $3.33, delivering a surprise of +3.10%. The market expects AbbVie (ABBV) to deliver a year-... |
23,666 | 2022-01-26 00:00:00 UTC | 2 Reasons to Buy AbbVie Stock, and 1 Reason to Sell | ABBV | https://www.nasdaq.com/articles/2-reasons-to-buy-abbvie-stock-and-1-reason-to-sell | null | null | With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. And given its massive pipeline of late-stage, drug-development programs in immunology, oncology, and aesthetics, the company likely has the opportunity to keep growing at a steady pace f... | With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. Let's take a peek at two compelling reasons to buy the shares of AbbVie and one significant reason it might be better to avoid or sell -- so that you'll know whether any potential tribul... | In 2023, remaining exclusivity protections will expire for Humira, AbbVie's drug for treating arthritis. With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. Let's take a peek at two compelling reasons to buy the shares of AbbVie and one s... | 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. Let's take a peek at two compelling reasons to buy the shares of AbbVie an... | With 2021 net revenue estimated at $56.2 billion, AbbVie (NYSE: ABBV) is one of the world's most successful pharmaceutical companies. Let's take a peek at two compelling reasons to buy the shares of AbbVie and one significant reason it might be better to avoid or sell -- so that you'll know whether any potential tribul... |
23,667 | 2022-01-26 00:00:00 UTC | 2 Stocks to Buy No Matter What Happens in 2022 | ABBV | https://www.nasdaq.com/articles/2-stocks-to-buy-no-matter-what-happens-in-2022-0 | null | null | The U.S. equity market has been quite volatile in January 2022. Rising omicron cases, sticky inflation, which is expected to result in rate hikes, and now weaker-than-anticipated earnings results for tech stocks have negatively affected investor sentiment. Against this backdrop, CNBC's Jim Cramer expects the S&P 500 to... | PFE PE Ratio (Forward) data by YCharts Despite the solid growth prospects, Pfizer trades at only 8.3 times forward earnings, significantly lower than peers, such as Merck, Johnson & Johnson, and AbbVie. While short- to mid-term investors may need to brace themselves for continued rockiness in the market in 2022, those ... | PFE PE Ratio (Forward) data by YCharts Despite the solid growth prospects, Pfizer trades at only 8.3 times forward earnings, significantly lower than peers, such as Merck, Johnson & Johnson, and AbbVie. The Motley Fool owns and recommends Apple, Qualcomm, and Taiwan Semiconductor Manufacturing. The Motley Fool recommen... | PFE PE Ratio (Forward) data by YCharts Despite the solid growth prospects, Pfizer trades at only 8.3 times forward earnings, significantly lower than peers, such as Merck, Johnson & Johnson, and AbbVie. According to Counterpoint, Qualcomm accounted for 27% market share in the global smartphone application-processor mar... | PFE PE Ratio (Forward) data by YCharts Despite the solid growth prospects, Pfizer trades at only 8.3 times forward earnings, significantly lower than peers, such as Merck, Johnson & Johnson, and AbbVie. According to Grand View Research, the global 5G chipset market is expected to grow to $66.45 billion in 2028, with a ... |
23,668 | 2022-01-25 00:00:00 UTC | Noteworthy Tuesday Option Activity: ABBV, AMED, REKR | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity%3A-abbv-amed-rekr | null | null | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 32,524 contracts have traded so far, representing approximately 3.3 million underlying shares. That amounts to about 44.1% of ABBV's average daily trading volume over ... | Especially high volume was seen for the $145 strike call option expiring February 18, 2022, with 6,845 contracts trading so far today, representing approximately 684,500 underlying shares of ABBV. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Sy... | Especially high volume was seen for the $145 strike call option expiring February 18, 2022, with 6,845 contracts trading so far today, representing approximately 684,500 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $145 strike highlighted in orange: Amedisys... | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in AbbVie Inc (Symbol: ABBV), where a total of 32,524 contracts have traded so far, representing approximately 3.3 million underlying shares. Especially high volume was seen for the $145 strike call option expiring... | Below is a chart showing REKR's trailing twelve month trading history, with the $10 strike highlighted in orange: For the various different available expirations for ABBV options, AMED options, or REKR options, visit StockOptionsChannel.com. Among the underlying components of the Russell 3000 index, we saw noteworthy o... |
23,669 | 2022-01-25 00:00:00 UTC | J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss | ABBV | https://www.nasdaq.com/articles/jj-jnj-q4-earnings-beat-estimates-by-a-penny-sales-miss | null | null | Johnson & Johnson’s JNJ fourth-quarter 2021 earnings came in at $2.13 per share, which beat the Zacks Consensus Estimate of $2.12 by a penny. Earnings increased 14.5% from the year-ago period.
Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported fourth-quar... | COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition have been hurting sales of J&J and AbbVie’s Imbruvica for the past couple of quarters. J&J markets Imbruvica in partnership with AbbVie ABBV. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition have been hurting sales of J&J and AbbVie’s Imbruvica for the past couple of quarters. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition have been hurting sales of J&J and AbbVie’s Imbruvica for the past couple of quarters. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition have been hurting sales of J&J and AbbVie’s Imbruvica for the past couple of quarters. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,670 | 2022-01-25 00:00:00 UTC | Johnson & Johnson (JNJ) Surpasses Q4 Earnings Estimates | ABBV | https://www.nasdaq.com/articles/johnson-johnson-jnj-surpasses-q4-earnings-estimates | null | null | Johnson & Johnson (JNJ) came out with quarterly earnings of $2.13 per share, beating the Zacks Consensus Estimate of $2.12 per share. This compares to earnings of $1.86 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 0.47%. A quarter ago... | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended December 2021. AbbVie's revenues are expected to be $15.07 billion, up 8.7% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended December 2021. AbbVie's revenues are expected to be $15.07 billion, up 8.7% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended December 2021. AbbVie's revenues are expected to be $15.07 billion, up 8.7% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | One other stock from the same industry, AbbVie (ABBV), is yet to report results for the quarter ended December 2021. AbbVie's revenues are expected to be $15.07 billion, up 8.7% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,671 | 2022-01-24 00:00:00 UTC | AbbVie's (ABBV) Skyrizi Gets FDA Nod for Psoriatic Arthritis | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-skyrizi-gets-fda-nod-for-psoriatic-arthritis | null | null | AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis.
Please note that Skyrizi was first approved to treat moderate-to-severe plaque psoriasis in 2019. Active psoriatic arthritis is the second FDA-appro... | AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis. AbbVie’s stock has risen 19.4% in the past year compared with an increase of 9.7% for the industry. AbbVie is developing Skyrizi in collaboration wi... | AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Stocks to Consider AbbVie currently carries a Zacks Rank #3 (Hold). AbbVie’s st... | AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis. AbbVie remains focused on strengthening its focus on Skyrizi and its other inflammatory drug Rinvoq to gradually lower its dependence on Humira, the... | AbbVie, Inc. ABBV announced that the FDA approved a second indication for its inflammatory drug, Skyrizi (risankizumab), to treat patients with active psoriatic arthritis. AbbVie’s stock has risen 19.4% in the past year compared with an increase of 9.7% for the industry. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,672 | 2022-01-24 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-0 | null | null | AbbVie (ABBV) closed the most recent trading day at $132.16, moving +0.14% from the previous trading session. This change lagged the S&P 500's 0.28% gain on the day. At the same time, the Dow added 0.29%, and the tech-heavy Nasdaq gained 0.19%.
Coming into today, shares of the drugmaker had lost 0.83% in the past month... | AbbVie (ABBV) closed the most recent trading day at $132.16, moving +0.14% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.29 per share. | AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie (ABBV) closed the most recent trading day at $132.16, moving +0.14% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. | AbbVie (ABBV) closed the most recent trading day at $132.16, moving +0.14% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.29 per share. | AbbVie (ABBV) closed the most recent trading day at $132.16, moving +0.14% from the previous trading session. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. In that report, analysts expect AbbVie to post earnings of $3.29 per share. |
23,673 | 2022-01-24 00:00:00 UTC | These High-Yield Dividend Stocks Are Growing at Blazing Speeds | ABBV | https://www.nasdaq.com/articles/these-high-yield-dividend-stocks-are-growing-at-blazing-speeds | null | null | Are you looking for the best of both worlds from your stock picks? That is to say, do you want strong dividend yields as well as growth? Such names are few and far between. In many cases, you get one or the other.
There are some stocks, however, that offer above-average dividend payouts as well as above-average growth ... | The drug is set to lose the bulk of its U.S. patent protection in 2023, one of the key reasons AbbVie shares have underperformed for years, allowing the dividend yield to inch up to its current 4.1%. AbbVie AbbVie (NYSE: ABBV) is probably the most recognizable name you'll find on this list of stocks. AbbVie is perhaps ... | Global Ship Lease While AbbVie may be a household name, Global Ship Lease (NYSE: GSL) is anything but. AbbVie AbbVie (NYSE: ABBV) is probably the most recognizable name you'll find on this list of stocks. AbbVie is perhaps most noteworthy for making arthritis, psoriasis, and Crohn's disease treatment, Humira, which is ... | Global Ship Lease While AbbVie may be a household name, Global Ship Lease (NYSE: GSL) is anything but. AbbVie AbbVie (NYSE: ABBV) is probably the most recognizable name you'll find on this list of stocks. AbbVie is perhaps most noteworthy for making arthritis, psoriasis, and Crohn's disease treatment, Humira, which is ... | * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie AbbVie (NYSE: ABBV) is probably the most recognizable name you'll find on this list of stocks. AbbVie is perhaps most noteworthy for making arthritis, psoriasis, and Crohn's disease tre... |
23,674 | 2022-01-24 00:00:00 UTC | 3 No-Brainer Healthcare Stocks to Buy Right Now for Less than $150 | ABBV | https://www.nasdaq.com/articles/3-no-brainer-healthcare-stocks-to-buy-right-now-for-less-than-%24150 | null | null | Over the past few months, the stock market has been experiencing sell-offs which has created great buying opportunities for wise investors. There's nothing like getting a high-quality long-term investment at bargain prices. Shares of AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and CVS Health (NYSE: CVS) all are below $150.... | However, as Humira's sales ebb, AbbVie has begun to replace them with its other two top performers, Skyrizi and Rinvoq, both immunological drugs. Merck is a solid choice, and because Keytruda's patent cliff is farther away than that of AbbVie's Humira, represents less risk, though its high dividend payout is something ... | Shares of AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and CVS Health (NYSE: CVS) all are below $150. Yes, AbbVie is doing great, but what about the Humira patent cliff? AbbVie has more going on than just Humira Pharmaceutical company AbbVie is up more than 20% over the past year and down 2% so far this year. | Shares of AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and CVS Health (NYSE: CVS) all are below $150. Yes, AbbVie is doing great, but what about the Humira patent cliff? AbbVie has more going on than just Humira Pharmaceutical company AbbVie is up more than 20% over the past year and down 2% so far this year. | AbbVie has more going on than just Humira Pharmaceutical company AbbVie is up more than 20% over the past year and down 2% so far this year. Shares of AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and CVS Health (NYSE: CVS) all are below $150. Yes, AbbVie is doing great, but what about the Humira patent cliff? |
23,675 | 2022-01-23 00:00:00 UTC | Is AbbVie Stock a Top Pick for 2022? | ABBV | https://www.nasdaq.com/articles/is-abbvie-stock-a-top-pick-for-2022 | null | null | Inflation is rampant. Treasury yields are rising, and the Federal Reserve is expected to raise interest rates multiple times in 2022. Many growth and technology stocks are getting hammered as a result, and investors are looking for a safe haven. In the case of AbbVie (NYSE: ABBV), look no further.
AbbVie is a global pr... | Risks are being managed well Many people know AbbVie as the company that makes the blockbuster biologic drug Humira which treats a long list of health conditions. While the market adjusts to the macroeconomic conditions of 2022, investors can relax and bank dividends from AbbVie without worrying about short-term stock ... | Next, AbbVie released Skyrizi and Rinvoq, two medications that are now expected to provide a combined $15 billion in sales by 2025. Despite the looming patent cliff, AbbVie looks safe AbbVie's management is seemingly doing everything correctly. In the case of AbbVie (NYSE: ABBV), look no further. | Risks are being managed well Many people know AbbVie as the company that makes the blockbuster biologic drug Humira which treats a long list of health conditions. While the market adjusts to the macroeconomic conditions of 2022, investors can relax and bank dividends from AbbVie without worrying about short-term stock ... | Long-term investors can buy AbbVie for the 4% yield and hold for the rising dividend and share price. In the case of AbbVie (NYSE: ABBV), look no further. AbbVie is a global prescription drug developer, manufacturer, and distributor that was spun off from parent company Abbott Labs back in 2013. |
23,676 | 2022-01-22 00:00:00 UTC | 1 Top Dividend Stock to Buy Right Now | ABBV | https://www.nasdaq.com/articles/1-top-dividend-stock-to-buy-right-now | null | null | Whether you're an experienced investor or brand new to investing, dividend stocks can provide an excellent means of increasing your portfolio returns while generating consistent capital to save or reinvest into your portfolio.
In this segment of Backstage Pass recorded on Jan. 5, Motley Fool contributor Rachel Warren d... | If I had to pick one stock in the healthcare space for investors to look at right now, check out AbbVie (NYSE: ABBV), classic value and dividend play, really diversified portfolio of products. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. * They just rev... | 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! If I had to pick one stock in the healthcare space for investors to look at righ... | If I had to pick one stock in the healthcare space for investors to look at right now, check out AbbVie (NYSE: ABBV), classic value and dividend play, really diversified portfolio of products. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. * They just rev... | 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! If I had to pick one stock in the healthcare space for investors to look at righ... |
23,677 | 2022-01-22 00:00:00 UTC | 3 Clinical Trials to Watch in the First Half of 2022 | ABBV | https://www.nasdaq.com/articles/3-clinical-trials-to-watch-in-the-first-half-of-2022 | null | null | Quite a few biopharmaceutical companies expect to report key clinical data in the coming months. In this Motley Fool Live video recorded on Jan. 12, 2022, Fool contributors Keith Speights and Brian Orelli discuss three clinical trials especially worth watching in the first half of 2022.
10 stocks we like better than Ar... | Brian Orelli: AbbVie, when they run their phase 3 clinical trial, they're almost going to have to do a head-to-head clinical-trial compared to doing it versus placebo. Then finally, AbbVie (NYSE: ABBV) should have some phase 2 data for its triple combination for cystic fibrosis. I saw that Vertex presented at J.P. Morg... | Keith Speights owns AbbVie, Pfizer, and Vertex Pharmaceuticals. Then finally, AbbVie (NYSE: ABBV) should have some phase 2 data for its triple combination for cystic fibrosis. I saw that Vertex presented at J.P. Morgan [its Jan. 10 healthcare conference], and they didn't sound like they were too worried about AbbVie's ... | Then finally, AbbVie (NYSE: ABBV) should have some phase 2 data for its triple combination for cystic fibrosis. I saw that Vertex presented at J.P. Morgan [its Jan. 10 healthcare conference], and they didn't sound like they were too worried about AbbVie's potential competition. They have such a lock on the market, and ... | Keith Speights owns AbbVie, Pfizer, and Vertex Pharmaceuticals. Then finally, AbbVie (NYSE: ABBV) should have some phase 2 data for its triple combination for cystic fibrosis. I saw that Vertex presented at J.P. Morgan [its Jan. 10 healthcare conference], and they didn't sound like they were too worried about AbbVie's ... |
23,678 | 2022-01-22 00:00:00 UTC | 2 Healthcare Stocks You Can Buy and Hold for the Next Decade | ABBV | https://www.nasdaq.com/articles/2-healthcare-stocks-you-can-buy-and-hold-for-the-next-decade-0 | null | null | Investors have been stuck on a roller coaster of volatility in the overall market for nearly two months, leading some to eye dividend stocks to cushion the fall. But Abbott Laboratories (NYSE: ABT) and UnitedHealth Group (NYSE: UNH) give investors more than that one reason to be comfortable with an investment in these ... | To put this number more in perspective of its strength, Abbott's top competitors -- Abbvie, Agilent Technologies, and Johnson & Johnson -- all grew revenue around 11% year over year in their latest quarters, including sales from Covid related items. FDA approvals of these devices could make a significant positive impac... | To put this number more in perspective of its strength, Abbott's top competitors -- Abbvie, Agilent Technologies, and Johnson & Johnson -- all grew revenue around 11% year over year in their latest quarters, including sales from Covid related items. Image Source: Getty Images Abbott Labs: a newly crowned king with doub... | To put this number more in perspective of its strength, Abbott's top competitors -- Abbvie, Agilent Technologies, and Johnson & Johnson -- all grew revenue around 11% year over year in their latest quarters, including sales from Covid related items. But Abbott Laboratories (NYSE: ABT) and UnitedHealth Group (NYSE: UNH)... | To put this number more in perspective of its strength, Abbott's top competitors -- Abbvie, Agilent Technologies, and Johnson & Johnson -- all grew revenue around 11% year over year in their latest quarters, including sales from Covid related items. Third-quarter revenue grew 23% year over year. Like Abbott, UnitedHeal... |
23,679 | 2022-01-21 00:00:00 UTC | Pharma Stock Roundup: GSK's Consumer Unit Offer Rejection, FDA Updates for AZN, PFE | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-gsks-consumer-unit-offer-rejection-fda-updates-for-azn-pfe | null | null | This week, Glaxo GSK rejected a $68 billion buyout offer for its consumer healthcare business from consumer giant, Unilever. The FDA approved Pfizer PFE & AbbVie’s ABBV JAK inhibitor drugs to treat eczema and also granted priority review to AstraZeneca AZN and partner, Daiichi Sankyo’s supplemental biologics license ap... | The FDA also approved AbbVie’s JAK inhibitor, Rinvoq (upadacitinib), for treating moderate-to-severe atopic dermatitis in adults and children (12 years and older) in patients who have had an inadequate response to other pills or injections, including biologic medicines. The FDA approved Pfizer PFE & AbbVie’s ABBV JAK i... | The FDA approved Pfizer PFE & AbbVie’s ABBV JAK inhibitor drugs to treat eczema and also granted priority review to AstraZeneca AZN and partner, Daiichi Sankyo’s supplemental biologics license application (sBLA), seeking approval for cancer drug Enhertu for expanded use in breast cancer. FDA Approves Pfizer & AbbVie’s ... | The FDA approved Pfizer PFE & AbbVie’s ABBV JAK inhibitor drugs to treat eczema and also granted priority review to AstraZeneca AZN and partner, Daiichi Sankyo’s supplemental biologics license application (sBLA), seeking approval for cancer drug Enhertu for expanded use in breast cancer. FDA Approves Pfizer & AbbVie’s ... | FDA Approves Pfizer & AbbVie’s JAK inhibitor Drugs for Eczema: The FDA granted approval to Pfizer’s once-daily JAK1 inhibitor, Cibinqo (abrocitinib), for the treatment of moderate-to-severe atopic dermatitis or eczema in adults who are candidates for systemic therapy. The FDA approved Pfizer PFE & AbbVie’s ABBV JAK inh... |
23,680 | 2022-01-21 00:00:00 UTC | J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings | ABBV | https://www.nasdaq.com/articles/jj-jnj-to-set-the-stage-for-pharma-sector-q4-earnings | null | null | Johnson & Johnson JNJ will report fourth-quarter and full-year 2021 results on Jan 25, before market open. In the last-reported quarter, the company delivered an earnings surprise of 9.7%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the... | Last quarter, temporary COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition hurt sales of J&J and AbbVie’s Imbruvica to an extent. J&J markets Imbruvica in partnership with AbbVie ABBV. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. Last quarter, temporary COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition hurt sales of J&J and AbbVie’s Imbruvica to an extent. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. Last quarter, temporary COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition hurt sales of J&J and AbbVie’s Imbruvica to an extent. AbbVie Inc. (ABBV): Free Stock Analysis Report | J&J markets Imbruvica in partnership with AbbVie ABBV. Last quarter, temporary COVID-19 impacts on new patient starts and modest share loss in the United States to new oral competition hurt sales of J&J and AbbVie’s Imbruvica to an extent. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,681 | 2022-01-20 00:00:00 UTC | 3 Value Stocks Breaking out in 2022 | ABBV | https://www.nasdaq.com/articles/3-value-stocks-breaking-out-in-2022 | null | null | (0:30) - Recap of Last Weeks Episode
(5:45) - Finding Value Stocks With Room To Run: Growth and Value
(15:35) - Tracey’s Top Stock Picks
(26:00) - Episode Roundup: CMA, CROX, ABBV, ANDE, INGR,
Podcast@Zacks.com
Welcome to Episode #265 of the Value Investor Podcast.
Every week, Tracey Ryniec, the editor... | (0:30) - Recap of Last Weeks Episode (5:45) - Finding Value Stocks With Room To Run: Growth and Value (15:35) - Tracey’s Top Stock Picks (26:00) - Episode Roundup: CMA, CROX, ABBV, ANDE, INGR, Podcast@Zacks.com Welcome to Episode #265 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large pharmaceutical company w... | (0:30) - Recap of Last Weeks Episode (5:45) - Finding Value Stocks With Room To Run: Growth and Value (15:35) - Tracey’s Top Stock Picks (26:00) - Episode Roundup: CMA, CROX, ABBV, ANDE, INGR, Podcast@Zacks.com Welcome to Episode #265 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large pharmaceutical company w... | (0:30) - Recap of Last Weeks Episode (5:45) - Finding Value Stocks With Room To Run: Growth and Value (15:35) - Tracey’s Top Stock Picks (26:00) - Episode Roundup: CMA, CROX, ABBV, ANDE, INGR, Podcast@Zacks.com Welcome to Episode #265 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large pharmaceutical company w... | (0:30) - Recap of Last Weeks Episode (5:45) - Finding Value Stocks With Room To Run: Growth and Value (15:35) - Tracey’s Top Stock Picks (26:00) - Episode Roundup: CMA, CROX, ABBV, ANDE, INGR, Podcast@Zacks.com Welcome to Episode #265 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large pharmaceutical company w... |
23,682 | 2022-01-20 00:00:00 UTC | Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist | ABBV | https://www.nasdaq.com/articles/top-biotech-stocks-to-buy-now-5-for-your-late-january-watchlist | null | null | Here Are 5 Biotech Stocks To Check Out In The Stock Market Today
As we move into the rest of 2022, it seems that biotech stocks could continue to be a viable play in the stock market. This can be attributed to the ongoing coronavirus concerns fueling the booming industry. Now, as the Omicron variant sweeps the globe, i... | Top Biotech Stocks To Watch In January 2022 Zogenix Inc. (NASDAQ: ZGNX) Valneva SE (NASDAQ: VALN) Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Zogenix Shares of small-cap biotech stock Zogenix have been moving higher this week. 5 For Your List AbbVie Leading biopharmaceutical company Abb... | Top Biotech Stocks To Watch In January 2022 Zogenix Inc. (NASDAQ: ZGNX) Valneva SE (NASDAQ: VALN) Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Zogenix Shares of small-cap biotech stock Zogenix have been moving higher this week. 5 For Your List AbbVie Leading biopharmaceutical company Abb... | Top Biotech Stocks To Watch In January 2022 Zogenix Inc. (NASDAQ: ZGNX) Valneva SE (NASDAQ: VALN) Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Zogenix Shares of small-cap biotech stock Zogenix have been moving higher this week. 5 For Your List AbbVie Leading biopharmaceutical company Abb... | Top Biotech Stocks To Watch In January 2022 Zogenix Inc. (NASDAQ: ZGNX) Valneva SE (NASDAQ: VALN) Pfizer Inc. (NYSE: PFE) Novavax Inc. (NASDAQ: NVAX) AbbVie Inc. (NYSE: ABBV) Zogenix Shares of small-cap biotech stock Zogenix have been moving higher this week. 5 For Your List AbbVie Leading biopharmaceutical company Abb... |
23,683 | 2022-01-20 00:00:00 UTC | 3 Dividend Aristocrats Yielding Over 4% | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-yielding-over-4 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
When it comes to income investing, we prefer dividend stocks that have demonstrated long histories of being able to raise their dividends throughout all kinds of economic conditions. There are many ways to find stocks with great dividend longevity, but one ... | That drug is rapidly approaching patent expiration in a variety of developed markets, including the U.S. AbbVie has a replacement for Humira, and it has acquired and built several other products to help offset this revenue cliff, but it is a concern nonetheless for near-term growth. These companies have stood the test ... | They are: Leggett & Platt (NYSE:LEG) AbbVie (NYSE:ABBV) Chevron (NYSE:CVX) Dividend Aristocrats: Leggett & Platt (LEG) Source: Casimiro PT / Shutterstock.com Our first Dividend Aristocrat is Leggett & Platt, a company that designs, manufactures and sells engineered components and other products globally. AbbVie (ABBV) ... | They are: Leggett & Platt (NYSE:LEG) AbbVie (NYSE:ABBV) Chevron (NYSE:CVX) Dividend Aristocrats: Leggett & Platt (LEG) Source: Casimiro PT / Shutterstock.com Our first Dividend Aristocrat is Leggett & Platt, a company that designs, manufactures and sells engineered components and other products globally. AbbVie (ABBV) ... | They are: Leggett & Platt (NYSE:LEG) AbbVie (NYSE:ABBV) Chevron (NYSE:CVX) Dividend Aristocrats: Leggett & Platt (LEG) Source: Casimiro PT / Shutterstock.com Our first Dividend Aristocrat is Leggett & Platt, a company that designs, manufactures and sells engineered components and other products globally. AbbVie (ABBV) ... |
23,684 | 2022-01-19 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie | null | null | At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2021 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 16 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2021 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 16 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the ... | Existing +56 +$1,376 Ridgecrest Wealth Partners LLC Existing +74 +$320 WT Wealth Management NEW +1,596 +$216 Intelligence Driven Advisers LLC NEW +4,832 +$662 YorkBridge Wealth Partners LLC Existing -100 +$439 Aggregate Change: -4,402 +$5,846 In terms of shares owned, we count 7 of the above funds having increased exis... | Existing +56 +$1,376 Ridgecrest Wealth Partners LLC Existing +74 +$320 WT Wealth Management NEW +1,596 +$216 Intelligence Driven Advisers LLC NEW +4,832 +$662 YorkBridge Wealth Partners LLC Existing -100 +$439 Aggregate Change: -4,402 +$5,846 In terms of shares owned, we count 7 of the above funds having increased exis... | At Holdings Channel, we have reviewed the latest batch of the 22 most recent 13F filings for the 12/31/2021 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 16 of these funds. Ferguson Wellman Capital Management Inc. 499,387 4-10 Find out the full Top 10 Hedge Funds Holding ABBV » We'll keep fol... |
23,685 | 2022-01-19 00:00:00 UTC | 3 Healthcare Stocks Ignoring the Market Mayhem | ABBV | https://www.nasdaq.com/articles/3-healthcare-stocks-ignoring-the-market-mayhem | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Traders returned from the holiday-lengthened weekend to a wave of selling. Small-caps and growth stocks remain the hardest hit, but just about everything got tossed out on Tuesday. The mayhem sent the Russell 2000 index over 3% and the Nasdaq down 2.5%. In ... | Bristol-Myers Squibb (NYSE:BMY) Abbvie (NYSE:ABBV) CVS Health (NYSE:CVS) Let’s take a closer look at each stock and identify an options trade that you can use to capitalize on further upside. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade The price of Abbvie enjoyed a banner year in 2021, with an ep... | Bristol-Myers Squibb (NYSE:BMY) Abbvie (NYSE:ABBV) CVS Health (NYSE:CVS) Let’s take a closer look at each stock and identify an options trade that you can use to capitalize on further upside. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade The price of Abbvie enjoyed a banner year in 2021, with an ep... | Bristol-Myers Squibb (NYSE:BMY) Abbvie (NYSE:ABBV) CVS Health (NYSE:CVS) Let’s take a closer look at each stock and identify an options trade that you can use to capitalize on further upside. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade The price of Abbvie enjoyed a banner year in 2021, with an ep... | Bristol-Myers Squibb (NYSE:BMY) Abbvie (NYSE:ABBV) CVS Health (NYSE:CVS) Let’s take a closer look at each stock and identify an options trade that you can use to capitalize on further upside. Abbvie (ABBV) Source: The thinkorswim® platform from TD Ameritrade The price of Abbvie enjoyed a banner year in 2021, with an ep... |
23,686 | 2022-01-19 00:00:00 UTC | 2 Best Warren Buffett Dividend Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/2-best-warren-buffett-dividend-stocks-to-buy-now | null | null | Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) CEO Warren Buffett is widely considered as one of the greatest investors of all time. One of Buffett's keys to success -- and a core lesson learned from his mentor Benjamin Graham -- has been to invest with a so-called "margin of safety." This concept centers on the idea o... | By 2025, though, AbbVie expects its top-line growth to ramp up in a significant way, thanks to the strength of its five core business segments in aesthetics, eye care, hematologic oncology, immunology, and neuroscience. Dividend-paying pharma stocks AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY) are both outs... | Dividend-paying pharma stocks AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY) are both outstanding buys for any type of investor right now. AbbVie: A high-yield, high-growth biopharma AbbVie is an oddball of sorts. Despite the looming U.S. patent expiration for its top drug Humira in 2023 and the ongoing bear ... | Despite the looming U.S. patent expiration for its top drug Humira in 2023 and the ongoing bear market in biopharma stocks in general, AbbVie's stock has produced total returns (including the dividend) on capital of a healthy 28.7% over the prior 12 months. Dividend-paying pharma stocks AbbVie (NYSE: ABBV) and Bristol ... | Dividend-paying pharma stocks AbbVie (NYSE: ABBV) and Bristol Myers Squibb (NYSE: BMY) are both outstanding buys for any type of investor right now. AbbVie: A high-yield, high-growth biopharma AbbVie is an oddball of sorts. Despite the looming U.S. patent expiration for its top drug Humira in 2023 and the ongoing bear ... |
23,687 | 2022-01-19 00:00:00 UTC | 3 Under-the-Radar COVID Stocks | ABBV | https://www.nasdaq.com/articles/3-under-the-radar-covid-stocks | null | null | COVID-19 has created a lot of volatility in the stock market. The whole market crashed in 2020, but many stocks quickly recovered. Indeed, there have been some high-flying pharmaceutical stocks that have skyrocketed as the biotech industry has fought back against the virus. And there are also some really interesting he... | So the OptimizeRx customer list is a who's who of Big Pharma: AbbVie, Amgen, AstraZeneca, Pfizer, Merck, Glaxo, Sanofi, Novartis, Medtronic, and more. Getting figgy with it Patrick Bafuma (FIGS): Thus far, each new COVID-19 variant has caused a wave of hospitalizations, and healthcare workers often find themselves work... | So the OptimizeRx customer list is a who's who of Big Pharma: AbbVie, Amgen, AstraZeneca, Pfizer, Merck, Glaxo, Sanofi, Novartis, Medtronic, and more. Multiple shots on goal George Budwell (NRx Pharmaceuticals): Although NRx Pharmaceuticals has gotten a fair amount of ink from several media outlets in recent months, th... | So the OptimizeRx customer list is a who's who of Big Pharma: AbbVie, Amgen, AstraZeneca, Pfizer, Merck, Glaxo, Sanofi, Novartis, Medtronic, and more. Here's why three Motley Fool contributors, in this roundtable discussion, think you might want to discover NRx Pharmaceuticals (NASDAQ: NRXP), FIGS (NYSE: FIGS), and Opt... | So the OptimizeRx customer list is a who's who of Big Pharma: AbbVie, Amgen, AstraZeneca, Pfizer, Merck, Glaxo, Sanofi, Novartis, Medtronic, and more. COVID-19 has created a lot of volatility in the stock market. NRx Pharmaceuticals is also developing a promising COVID-19 vaccine called briLife. |
23,688 | 2022-01-19 00:00:00 UTC | 3 Dividend Stocks to Buy and Hold Forever | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-to-buy-and-hold-forever | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Dividends are an important factor for many investors. The quarterly and annual payouts to shareholders can have a big impact on a portfolio’s growth over time. Dividend stocks can also serve as an income stream to people in retirement.
For this reason, many... | If there’s one drawback to investing in ABBV stock it is that the company is going to lose the patent exclusivity on its blockbuster medication Humira that is used to treat inflammatory bowel conditions, namely Crohn’s disease. Sales of Humira accounted for a third of AbbVie’s $14.4 billion in revenue during the third ... | AbbVie (NYSE:ABBV) Kroger (NYSE:KR) Chevron (NYSE:CVX) Dividend Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com Pharmaceutical manufacturer AbbVie has been a winner since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. In ... | AbbVie (NYSE:ABBV) Kroger (NYSE:KR) Chevron (NYSE:CVX) Dividend Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com Pharmaceutical manufacturer AbbVie has been a winner since it was spun off from Abbott Laboratories (NYSE:ABT) in 2013. In ... | In its nine years as a public company, ABBV stock has delivered a 300% return to shareholders, which is great in and of itself. Sales of Humira accounted for a third of AbbVie’s $14.4 billion in revenue during the third quarter of 2021, so the patent expiration in 2023 is going to be a big blow to the company’s finance... |
23,689 | 2022-01-18 00:00:00 UTC | 7 of the Top-Rated Pharmaceutical Stocks for Q1 | ABBV | https://www.nasdaq.com/articles/7-of-the-top-rated-pharmaceutical-stocks-for-q1 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Pharmaceutical stocks haven’t really had much since the pandemic hit. Most of the talk has been about the companies in a race for vaccines or treatments and the companies that are distributing vaccines and treatments.
That hasn’t left a lot of space for oth... | AbbVie (NYSE:ABBV) Catalyst Pharmaceuticals (NASDAQ:CPRX) Horizon Therapeutics (NASDAQ:HZNP) Innoviva (NASDAQ:INVA) Eli Lilly (NYSE:LLY) Pfizer (NYSE:PFE) Zoetis (NYSE:ZTS) Pharmaceutical Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com... | AbbVie (NYSE:ABBV) Catalyst Pharmaceuticals (NASDAQ:CPRX) Horizon Therapeutics (NASDAQ:HZNP) Innoviva (NASDAQ:INVA) Eli Lilly (NYSE:LLY) Pfizer (NYSE:PFE) Zoetis (NYSE:ZTS) Pharmaceutical Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com... | AbbVie (NYSE:ABBV) Catalyst Pharmaceuticals (NASDAQ:CPRX) Horizon Therapeutics (NASDAQ:HZNP) Innoviva (NASDAQ:INVA) Eli Lilly (NYSE:LLY) Pfizer (NYSE:PFE) Zoetis (NYSE:ZTS) Pharmaceutical Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com... | AbbVie (NYSE:ABBV) Catalyst Pharmaceuticals (NASDAQ:CPRX) Horizon Therapeutics (NASDAQ:HZNP) Innoviva (NASDAQ:INVA) Eli Lilly (NYSE:LLY) Pfizer (NYSE:PFE) Zoetis (NYSE:ZTS) Pharmaceutical Stocks to Buy: AbbVie (ABBV) ABBV) website and logo on mobile phone" width="300" height="169"> Source: Piotr Swat / Shutterstock.com... |
23,690 | 2022-01-18 00:00:00 UTC | Noteworthy ETF Inflows: VYM, VZ, ABBV, KO | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-inflows%3A-vym-vz-abbv-ko | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Vanguard High Dividend Yield ETF (Symbol: VYM) where we have detected an approximate $1.2 billion dollar inflow -- that's a 2.8% increase week over week in outstanding units (from 370,014,28... | Among the largest underlying components of VYM, in trading today Verizon Communications Inc (Symbol: VZ) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is off about 0.3%, and Coca-Cola Co (Symbol: KO) is lower by about 1.2%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year... | Among the largest underlying components of VYM, in trading today Verizon Communications Inc (Symbol: VZ) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is off about 0.3%, and Coca-Cola Co (Symbol: KO) is lower by about 1.2%. For a complete list of holdings, visit the VYM Holdings page » The chart below shows the one year... | Among the largest underlying components of VYM, in trading today Verizon Communications Inc (Symbol: VZ) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is off about 0.3%, and Coca-Cola Co (Symbol: KO) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ... | Among the largest underlying components of VYM, in trading today Verizon Communications Inc (Symbol: VZ) is off about 1.1%, AbbVie Inc (Symbol: ABBV) is off about 0.3%, and Coca-Cola Co (Symbol: KO) is lower by about 1.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ... |
23,691 | 2022-01-18 00:00:00 UTC | Zacks Industry Outlook Highlights: Roche, Pfizer, AbbVie and Merck | ABBV | https://www.nasdaq.com/articles/zacks-industry-outlook-highlights%3A-roche-pfizer-abbvie-and-merck | null | null | For Immediate Release
Chicago, IL – January 18, 2022 – Today, Zacks Equity Research discusses Roche RHHBY, Pfizer PFE, AbbVie ABBV and Merck MRK.
Industry: Big Pharma
Link:https://www.zacks.com/commentary/1851984/3-medical-services-stocks-to-buy-despite-near-term-industry-woes
The drug and biotech sectors remained in t... | For Immediate Release Chicago, IL – January 18, 2022 – Today, Zacks Equity Research discusses Roche RHHBY, Pfizer PFE, AbbVie ABBV and Merck MRK. Among the large drugmakers Roche, Pfizer, AbbVie and Merck are worth retaining in your portfolio. AbbVie: AbbVie has become one of the top-most pharma companies after it acqu... | For Immediate Release Chicago, IL – January 18, 2022 – Today, Zacks Equity Research discusses Roche RHHBY, Pfizer PFE, AbbVie ABBV and Merck MRK. Among the large drugmakers Roche, Pfizer, AbbVie and Merck are worth retaining in your portfolio. AbbVie: AbbVie has become one of the top-most pharma companies after it acqu... | For Immediate Release Chicago, IL – January 18, 2022 – Today, Zacks Equity Research discusses Roche RHHBY, Pfizer PFE, AbbVie ABBV and Merck MRK. Among the large drugmakers Roche, Pfizer, AbbVie and Merck are worth retaining in your portfolio. AbbVie: AbbVie has become one of the top-most pharma companies after it acqu... | For Immediate Release Chicago, IL – January 18, 2022 – Today, Zacks Equity Research discusses Roche RHHBY, Pfizer PFE, AbbVie ABBV and Merck MRK. Among the large drugmakers Roche, Pfizer, AbbVie and Merck are worth retaining in your portfolio. AbbVie: AbbVie has become one of the top-most pharma companies after it acqu... |
23,692 | 2022-01-17 00:00:00 UTC | AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-outpaces-stock-market-gains%3A-what-you-should-know-0 | null | null | AbbVie (ABBV) closed at $135.87 in the latest trading session, marking a +1.76% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.08%. Meanwhile, the Dow lost 0.56%, and the Nasdaq, a tech-heavy index, lost 4.81%.
Prior to today's trading, shares of the drugmaker had gained 4.89% over the past m... | AbbVie (ABBV) closed at $135.87 in the latest trading session, marking a +1.76% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.29 per share, which would represent year-over-year gro... | AbbVie (ABBV) closed at $135.87 in the latest trading session, marking a +1.76% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. On that day, AbbVie is projected to report earnings of $3.29 per share, which would represent year-over-year gro... | AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie (ABBV) closed at $135.87 in the latest trading session, marking a +1.76% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earnings report date. | On that day, AbbVie is projected to report earnings of $3.29 per share, which would represent year-over-year growth of 12.67%. AbbVie (ABBV) closed at $135.87 in the latest trading session, marking a +1.76% move from the prior day. Wall Street will be looking for positivity from AbbVie as it approaches its next earning... |
23,693 | 2022-01-17 00:00:00 UTC | AbbVie's (ABBV) Rinvoq Gets FDA Nod for Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/abbvies-abbv-rinvoq-gets-fda-nod-for-atopic-dermatitis | null | null | AbbVie Inc. ABBV announced that the FDA has approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication. The drug is now approved for the treatment of moderate to severe atopic dermatitis (“AD”) in adults and children aged 12 years and above whose disease did not respond to previous treatment and ... | AbbVie Inc. ABBV announced that the FDA has approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication. Shares of AbbVie have rallied 23% in the past year compared with the industry’s increase of 14.8%. Image Source: Zacks Investment Research Last month, AbbVie announced an update to the prescrib... | AbbVie Inc. ABBV announced that the FDA has approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication. Shares of AbbVie have rallied 23% in the past year compared with the industry’s increase of 14.8%. Image Source: Zacks Investment Research Last month, AbbVie announced an update to the prescrib... | AbbVie Inc. ABBV announced that the FDA has approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication. Shares of AbbVie have rallied 23% in the past year compared with the industry’s increase of 14.8%. Image Source: Zacks Investment Research Last month, AbbVie announced an update to the prescrib... | AbbVie Inc. ABBV announced that the FDA has approved its promising JAK inhibitor, Rinvoq (upadacitinib), for a new indication. Shares of AbbVie have rallied 23% in the past year compared with the industry’s increase of 14.8%. Image Source: Zacks Investment Research Last month, AbbVie announced an update to the prescrib... |
23,694 | 2022-01-17 00:00:00 UTC | Pfizer's (PFE) Cibinqo Gets FDA Nod for Atopic Dermatitis | ABBV | https://www.nasdaq.com/articles/pfizers-pfe-cibinqo-gets-fda-nod-for-atopic-dermatitis | null | null | Pfizer Inc. PFE announced that the FDA has approved its oral, once-daily, JAK1 inhibitor, Cibinqo (abrocitinib), for the treatment of refractory moderate-to-severe atopic dermatitis (AD) — also called eczema — in adult patients who did not respond to treatment with other drugs or when the use of other treatments is not... | Hence, the FDA limited the use of Xeljanz to certain patients who have not responded to or cannot tolerate one or more TNF blockers and issued a directive last September to add warnings about these increased risks on Xeljanz’s label This FDA directive was also extended to the labels of other JAK inhibitors medications,... | Hence, the FDA limited the use of Xeljanz to certain patients who have not responded to or cannot tolerate one or more TNF blockers and issued a directive last September to add warnings about these increased risks on Xeljanz’s label This FDA directive was also extended to the labels of other JAK inhibitors medications,... | Hence, the FDA limited the use of Xeljanz to certain patients who have not responded to or cannot tolerate one or more TNF blockers and issued a directive last September to add warnings about these increased risks on Xeljanz’s label This FDA directive was also extended to the labels of other JAK inhibitors medications,... | Hence, the FDA limited the use of Xeljanz to certain patients who have not responded to or cannot tolerate one or more TNF blockers and issued a directive last September to add warnings about these increased risks on Xeljanz’s label This FDA directive was also extended to the labels of other JAK inhibitors medications,... |
23,695 | 2022-01-17 00:00:00 UTC | The Zacks Analyst Blog Highlights: Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-pfizer-pfe-beam-therapeutics-abbvie-merck-and-glaxo | null | null | For Immediate Release
Chicago, IL – January 17, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer PFE, Beam Therapeut... | AbbVie has submitted regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of Rinvoq (upadacitinib) for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA). Stocks recently featured in the blog include: Pfizer PFE, Beam Therapeutics BEAM,AbbVie ABBV,... | Stocks recently featured in the blog include: Pfizer PFE, Beam Therapeutics BEAM,AbbVie ABBV, Merck’s (MRK) and Glaxo GSK. AbbVie maintained its long-term sales outlook for the two most promising new drugs, Skyrizi and Rinvoq. AbbVie Retains Rinvoq/Skyrizi Combined Guidance: AbbVie retained its previously issued combin... | Stocks recently featured in the blog include: Pfizer PFE, Beam Therapeutics BEAM,AbbVie ABBV, Merck’s (MRK) and Glaxo GSK. AbbVie maintained its long-term sales outlook for the two most promising new drugs, Skyrizi and Rinvoq. AbbVie Retains Rinvoq/Skyrizi Combined Guidance: AbbVie retained its previously issued combin... | Stocks recently featured in the blog include: Pfizer PFE, Beam Therapeutics BEAM,AbbVie ABBV, Merck’s (MRK) and Glaxo GSK. AbbVie maintained its long-term sales outlook for the two most promising new drugs, Skyrizi and Rinvoq. AbbVie Retains Rinvoq/Skyrizi Combined Guidance: AbbVie retained its previously issued combin... |
23,696 | 2022-01-17 00:00:00 UTC | Is AbbVie a Good Dividend Stock to Buy Right Now? | ABBV | https://www.nasdaq.com/articles/is-abbvie-a-good-dividend-stock-to-buy-right-now | null | null | If you're looking for better-than-average dividend yields, there's a pharmaceutical stock you need to take a look at. At recent prices, AbbVie (NYSE: ABBV) offers a 4.1% dividend yield that's impossible to ignore.
Over the past year, the average dividend-paying stock in the S&P 500 index delivered a lousy 1.3% yield. I... | U.S. Humira sales contributed $4.6 billion to AbbVie's top line during the third quarter, so replacing lost revenue from this drug is going to be a major challenge. Despite hiking its payout, AbbVie was able to meet its obligation using just 42% of the free cash flow its lucrative pharmaceutical operations generated ov... | In a nutshell, fear of declining sales for AbbVie's lead drug, Humira, is the reason AbbVie offers a huge dividend yield that is more than double the benchmark average. With a dividend program already on solid footing and new drugs driving growth, AbbVie looks like a great dividend stock to buy right now. At recent pri... | In a nutshell, fear of declining sales for AbbVie's lead drug, Humira, is the reason AbbVie offers a huge dividend yield that is more than double the benchmark average. Label expansions in and outside of the U.S. recently gave AbbVie the confidence to predict over $15 billion in combined annual sales from Rinvoq and Sk... | Rinvoq is a treatment for rheumatoid arthritis that AbbVie launched in 2019. At recent prices, AbbVie (NYSE: ABBV) offers a 4.1% dividend yield that's impossible to ignore. If the big yield AbbVie offers seems a little too good to be true, it's because there's a catch. |
23,697 | 2022-01-16 00:00:00 UTC | Abbvie Inc Shares Near 52-Week High - Market Mover | ABBV | https://www.nasdaq.com/articles/abbvie-inc-shares-near-52-week-high-market-mover-2 | null | null | Abbvie Inc (ABBV) shares closed today at 0.6% below its 52 week high of $136.73, giving the company a market cap of $240B. The stock is currently up 1.4% year-to-date, up 28.7% over the past 12 months, and up 175.9% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.... | Abbvie Inc (ABBV) shares closed today at 0.6% below its 52 week high of $136.73, giving the company a market cap of $240B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. | Abbvie Inc (ABBV) shares closed today at 0.6% below its 52 week high of $136.73, giving the company a market cap of $240B. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 20.0% higher than the 20-day average. | Abbvie Inc (ABBV) shares closed today at 0.6% below its 52 week high of $136.73, giving the company a market cap of $240B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the D... | Abbvie Inc (ABBV) shares closed today at 0.6% below its 52 week high of $136.73, giving the company a market cap of $240B. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
23,698 | 2022-01-16 00:00:00 UTC | 3 Pharma Stocks With Especially Juicy Dividends | ABBV | https://www.nasdaq.com/articles/3-pharma-stocks-with-especially-juicy-dividends | null | null | Big pharmaceutical companies usually make big bucks. And many of them return a portion of their profits to investors in the form of dividends.
We asked three Motley Fool contributors to pick the pharma stocks that they think have especially juicy dividends. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NA... | Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A Dividend Aristocrat that's performing well Keith Speights (AbbVie): There's so much to like about AbbVie's dividend that it's hard to know where to begin. What's even better, though, is that AbbVie is a Dividend Aristoc... | Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A Dividend Aristocrat that's performing well Keith Speights (AbbVie): There's so much to like about AbbVie's dividend that it's hard to know where to begin. What's even better, though, is that AbbVie is a Dividend Aristoc... | What's even better, though, is that AbbVie is a Dividend Aristocrat -- an elite group of S&P 500 members that have increased their dividends for at least 25 consecutive years. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). A Dividend Aristocrat that's performing well ... | A Dividend Aristocrat that's performing well Keith Speights (AbbVie): There's so much to like about AbbVie's dividend that it's hard to know where to begin. Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE). What's even better, though, is that AbbVie is a Dividend Aristoc... |
23,699 | 2022-01-14 00:00:00 UTC | U.S. FDA approves drugs from AbbVie, Pfizer to treat eczema | ABBV | https://www.nasdaq.com/articles/u.s.-fda-approves-drugs-from-abbvie-pfizer-to-treat-eczema | null | null | Recasts to include approval for Pfizer's drug
Jan 14 (Reuters) - The U.S. Food and Drug Administration approved drugs from AbbVie Inc ABBV.N and Pfizer Inc PFE.N for treating eczema, a skin disease, the companies said on Friday.
AbbVie's Rinvoq and Pfizer's Cibinqo have been approved to treat moderate-to-severe atopic ... | Recasts to include approval for Pfizer's drug Jan 14 (Reuters) - The U.S. Food and Drug Administration approved drugs from AbbVie Inc ABBV.N and Pfizer Inc PFE.N for treating eczema, a skin disease, the companies said on Friday. AbbVie's Rinvoq and Pfizer's Cibinqo have been approved to treat moderate-to-severe atopic ... | Recasts to include approval for Pfizer's drug Jan 14 (Reuters) - The U.S. Food and Drug Administration approved drugs from AbbVie Inc ABBV.N and Pfizer Inc PFE.N for treating eczema, a skin disease, the companies said on Friday. AbbVie's Rinvoq and Pfizer's Cibinqo have been approved to treat moderate-to-severe atopic ... | Recasts to include approval for Pfizer's drug Jan 14 (Reuters) - The U.S. Food and Drug Administration approved drugs from AbbVie Inc ABBV.N and Pfizer Inc PFE.N for treating eczema, a skin disease, the companies said on Friday. AbbVie's Rinvoq and Pfizer's Cibinqo have been approved to treat moderate-to-severe atopic ... | Both Pfizer and AbbVie cited risks of serious infections and cardiovascular events, among others. The FDA last month added its strictest warning to labels of JAK inhibitor drugs from Pfizer PFE.N, Eli Lilly LLY.N and AbbVie following a review of Pfizer's Xeljanz, another JAK inhibitor. Recasts to include approval for P... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.